EP2243499A2 - Wound closure material - Google Patents

Wound closure material Download PDF

Info

Publication number
EP2243499A2
EP2243499A2 EP10250641A EP10250641A EP2243499A2 EP 2243499 A2 EP2243499 A2 EP 2243499A2 EP 10250641 A EP10250641 A EP 10250641A EP 10250641 A EP10250641 A EP 10250641A EP 2243499 A2 EP2243499 A2 EP 2243499A2
Authority
EP
European Patent Office
Prior art keywords
article
copolymer
polymeric material
weight
inches
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10250641A
Other languages
German (de)
French (fr)
Other versions
EP2243499A3 (en
Inventor
Joshua Stopek
Amin Elachchabi
Roland Ostapoff
Brian Nentwick
Richard Stevenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covidien LP
Original Assignee
Tyco Healthcare Group LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyco Healthcare Group LP filed Critical Tyco Healthcare Group LP
Publication of EP2243499A2 publication Critical patent/EP2243499A2/en
Publication of EP2243499A3 publication Critical patent/EP2243499A3/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B17/07292Reinforcements for staple line, e.g. pledgets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00526Methods of manufacturing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831Material properties
    • A61B2017/00893Material properties pharmaceutically effective
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/44Radioisotopes, radionuclides

Definitions

  • the present disclosure relates to articles of polymeric materials in tape, ribbon, sheet, and/or film configurations. These polymeric materials may be formed so that they possess no orientation or multi-directional orientation, which may enhance the integrity of the polymeric material when multidirectional forces are applied thereto.
  • the polymeric materials of the present disclosure may be utilized in numerous applications including, in embodiments, as surgical buttresses or reinforcing tapes for staple or suture lines.
  • Films, ribbons, sheets, tapes, and the like which are made of polymeric materials are within the purview of those skilled in the art. Such materials may be produced by melting the polymeric material, extruding the material through a die, and then cooling the resulting material. This process may be very similar to methods utilized for forming filaments or films. The resulting material may be subsequently drawn at various draw ratios through a series of draw stations coupled with heated ovens or similar means in various configurations. This process may be coupled or de-coupled. The resulting drawn material, which may be in the form of a film, ribbon, sheet, tape, and the like, is usually highly oriented in a single direction, i.e., it possesses unidirectional orientation, linearly down its length (the direction in which it was drawn).
  • the straight pull tensile properties of these materials are usually measured in the same direction as their orientation. Such materials may thus possess great strength when pull forces are applied along the length of the material. While this unidirectional orientation may be desirable for certain uses, for example where similar extrusion, spinning and drawing methods are utilized to produce fibers such as sutures, filaments, and the like, such methods to produce tapes, ribbons, sheets, films, and the like may not be as desirable. This may be especially so where forces which are perpendicular to the unidirectional orientation of the material are applied, which may result in punctures, tears, or cuts in the polymeric material. In some cases, these tears may occur with the application of little force, which may be undesirable.
  • Surgical stapling devices have found widespread application in surgical operations where body tissue is joined or removed. While buttresses may be used in conjunction with stapling devices or sutures to enhance sealing of wounds, materials possessing a unidirectional orientation as described above may crack or tear with the application of small amounts of force. Moreover, when these materials are perforated by a staple or needle, propagating tears may form parallel to the unidirectional orientation, leading to premature material failure when forces are applied perpendicular to the orientation of the polymer.
  • a method including obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof; forming the polymeric material into an article that does not possess orientation in a single direction; contacting the polymeric material with at least one agent such as paclitaxel, DHA-paclitaxel, doxetaxel, abraxane, 5-fluorouracil (5-FU), mitoxantrone, daunorubicin, doxorubicin, cisplatin, carboplatin, methotrexate, bevacizumab, antibody and prodrug conjugates of these, HER-2/neu peptides, proteins, and related vaccines, iodine 125, palladium 103, iridium 192, cesium 131, gold 198, yttrium 90, phosphorus 32, and combinations thereof, and recovering
  • the polymeric material comprises a copolymer including glycolide in amounts from about 60% to about 75% by weight of the copolymer and trimethylene carbonate in amounts from about 25% to about 40% by weight of the copolymer.
  • the polymeric material comprises a copolymer including glycolide in amounts from about 55% to about 65% by weight of the copolymer, dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer.
  • the polymeric material comprises a copolymer including caprolactone in amounts from about 14% to about 20% by weight of the copolymer, lactide in amounts from about 4% to about 10% by weight of the copolymer, trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, and glycolide in amounts from about 60% to about 78% by weight of the copolymer.
  • the step of forming the polymeric material into an article comprises forming an article selected from the group consisting of ribbons, tapes, sheets, and films.
  • the step of forming the polymeric material into an article that does not possess orientation in a single direction results in an article possessing no orientation.
  • the step of forming the polymeric material into an article that does not possess orientation in a single direction results in an article possessing multi-directional orientation.
  • the step of forming the polymeric material into an article that does not possess orientation in a single direction occurs by a process selected from the group consisting of compression rollers, contoured rollers, heat pressing, blown film methods, and combinations thereof.
  • the step of forming the polymeric material into an article that does not possess orientation in a single direction occurs by subjecting the polymeric material to a temperature of from about 95°C to about 230°C and a pressure of from about 1 psi to about 2500 psi, for a period of time from about 5 seconds to about 10 minutes.
  • the step of forming the polymeric material into an article that does not possess orientation in a single direction occurs by introducing the polymeric material into a barrel heated to a temperature of from about 290° F to about 355° F, extruding the polymeric material through a die having a diameter of from about 1 inch to about 1.5 inches to produce a tubular film, expanding the tubular film to a diameter of from about 2 inches to about 4 inches, and flattening the tubular film to produce a film having a thickness from about 0.001 inches to about 0.014 inches.
  • the method further includes forming a texture on at least one surface of the article.
  • the article possesses a thickness of from about 0.0005 inches to about 0.014 inches.
  • the article possesses a thickness of from about 0.002 inches to about 0.005 inches.
  • a method for producing a surgical staple buttress.
  • a method for producing a suture line reinforcement strip.
  • a surgical stapling apparatus including a staple cartridge containing at least one staple; an anvil having a staple forming surface; and a buttress positioned adjacent the anvil or the cartridge, the buttress comprising an article produced by a method including obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof; forming the polymeric material into an article that does not possess orientation in a single direction; and recovering the article.
  • a method of sealing a wound including enclosing tissue between a cartridge and an anvil of a surgical stapling apparatus, one of the cartridge or anvil having a buttress positioned adjacent thereto, wherein the buttress comprises an article produced by a method including obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof; forming the polymeric material into an article that does not possess orientation in a single direction; and recovering the article; and ejecting staples from the cartridge to secure the buttress to the tissue.
  • Polymeric articles are provided that do not possess orientation in a single direction, i.e., they may have no orientation or multi-directional orientation.
  • the polymeric articles may be suitable for use in connection with a surgical stapling apparatus or similar wound closure devices to assist in the sealing of tissue to prevent the leakage of fluids and gases.
  • buttresses of the present disclosure may include multiple layers, optionally with coatings on at least a portion thereof.
  • the coating may include a bioactive agent, in embodiments a chemotherapeutic agent. Where a bioactive agent is present, the buttress may thus be utilized to deliver bioactive agents such as chemotherapeutic agents and other drugs.
  • Polymeric articles in the form of tapes, ribbons, sheets, films, and the like are provided in accordance with the present disclosure made of materials that are not highly oriented in a single direction, i.e., they may have no orientation or multi-directional orientation. Where the materials possess multi-directional orientation, the materials may be more oriented in one direction, with some orientation in a different direction, in embodiments a perpendicular direction, or the materials may possess omni-directional orientation, i.e., being oriented in all directions. In embodiments, the polymeric materials may be utilized to form buttresses or similar materials for use in conjunction with wound closure devices such as staplers and sutures to enhance wound closure.
  • Suitable materials for use in forming the polymeric tapes, ribbons, sheets, and films may include any biocompatible material.
  • the polymeric articles may be formed from a natural material or a synthetic material.
  • the polymeric article may be bioabsorbable or non-bioabsorbable. It should of course be understood that any combination of natural, synthetic, bioabsorbable and/or non-bioabsorbable materials may be used.
  • materials which may be used to form articles of the present disclosure include, but are not limited to, poly(lactic acid), poly (glycolic acid), poly (hydroxybutyrate), poly(phosphazine), polyesters, polyethylene glycols, polyethylene oxides, polyacrylamides, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly(ether-esters), polyalkylene oxalates, polyamides, poly(iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes and copolymers, block copolymers, homopolymers, blends and combinations thereof.
  • suitable materials which may be utilized to form the articles of the present disclosure such as tapes, ribbons, sheets, films, and the like, include homopolymers, copolymers, and/or blends possessing glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and various combinations of the foregoing.
  • a copolymer of glycolide and trimethylene carbonate may be utilized. Methods for forming such copolymers are within the purview of those skilled in the art and include, for example, the methods disclosed in U.S. Patent No. 4,300,565 , the entire disclosure of which is incorporated by reference herein.
  • Suitable copolymers of glycolide and trimethylene carbonate may possess glycolide in amounts from about 60% to about 75% by weight of the copolymer, in embodiments, from about 65% to about 70% by weight of the copolymer, with the trimethylene carbonate being present in amounts from about 25% to about 40% by weight of the copolymer, in embodiments from about 30% to about 35% by weight of the copolymer.
  • suitable materials for forming articles of the present disclosure include, in embodiments, copolymers of glycolide, dioxanone and trimethylene carbonate.
  • Such materials may include, for example, copolymers possessing glycolide in amounts from about 55% to about 65% by weight of the copolymer, in embodiments from about 58% to about 62% by weight of the copolymer, in some embodiments about 60% by weight of the copolymer; dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, in embodiments from about 12% to about 16 % by weight of the copolymer, in some embodiments about 14% by weight of the copolymer; and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer, in embodiments from about 22% to about 30% by weight of the copolymer, in embodiments about 26% by weight of the copolymer.
  • a copolymer of glycolide, lactide, trimethylene carbonate and ⁇ -caprolactone may be utilized to form an article of the present disclosure.
  • Such materials may include, for example, a random copolymer possessing caprolactone in amounts from about 14% to about 20% by weight of the copolymer, in embodiments from about 16% to about 18% by weight of the copolymer, in some embodiments about 17% by weight of the copolymer; lactide in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in some embodiments about 7% by weight of the copolymer; trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in embodiments about 7% by weight of the copolymer; and glycolide in amounts from about 60% to about 78% by weight of the copolymer,
  • the individual monomers may be combined in the presence of an initiator, such as diethylene glycol, and a catalyst, such as stannous octoate.
  • an initiator such as diethylene glycol
  • a catalyst such as stannous octoate.
  • the materials may be combined for a suitable period of time from about 4 hours to about 8 hours, in embodiments from about 5 hours to about 7 hours, in other embodiments for about 6 hours.
  • the mixture may be held under an inert atmosphere, such as under nitrogen gas.
  • the mixture may then heated to a temperature from about 80° C to about 120° C, in embodiments from about 90° C to about 110° C, in some cases to about 100° C, for a suitable period of time of from about 5 minutes to about 30 minutes, in embodiments from about 10 minutes to about 20 minutes, in other embodiments for about 15 minutes.
  • the reaction mixture may then be heated to a temperature from about 130° C to about 170° C, in embodiments from about 140° C to about 160° C, in embodiments to about 150° C, for a suitable period of time of from about 5 minutes to about 30 minutes, in embodiments from about 10 minutes to about 20 minutes, in other embodiments for about 15 minutes.
  • the mixture may then be heated to a temperature of from about 170° C to about 190° C, in embodiments to about 180° C, and allowed to polymerize for a period of from about 14 to about 24 hours, in embodiments from about 16 to about 20 hours, in some embodiments about 18 hours.
  • methods for forming articles such as ribbons, tapes, sheets, and/or films from these materials include, but are not limited to, the use of compression rollers, the use of contoured rollers, heat pressing, blown film methods, combinations thereof, and the like.
  • the polymer In a compression roller system, the polymer is melted and extruded from a die of a suitable thickness. As the polymer melt exits the extruder die it may be fed through two rollers opposite each other which press against each other and any film passing there between with sufficient pressure to compress the material to the desired thickness.
  • the rollers can both be cooled, both heated, or have one cooled and one heated. Any method within the purview of those skilled in the art may be utilized to heat and/or cool the rollers. Such methods include, for example, induction, jacketed, air heated, air cooled, contained in an oven or refrigerator, and the like.
  • the compressing rollers may rotate at about the same or close to the same speed as collection rollers used to advance the material through the system and match the rate of extrusion of material exiting the die.
  • the resulting article may be in a tape, ribbon, sheet, film, or similar configuration.
  • contoured rollers may be utilized instead of compression rollers to form the articles of the present disclosure.
  • Current draw station rollers may be cylindrical and draw spun-drawn polymeric material exiting an extruder in one direction leading to the unidirectional orientation of the resulting film.
  • laterally oriented non-cylindrical (e.g., spherical, football-shaped, elliptical) rollers between the draw stations may stretch the film laterally as it moves through the drawing process, thus resulting in both longitudinal and latitudinal orientation of the resulting film.
  • the multidirectional stretching and resulting multidirectional orientation may minimize or avoid the formation of fracture planes in the resulting material.
  • articles of the present disclosure may be formed utilizing a heat press, sometimes referred to herein as a heated hydraulic press.
  • Suitable heat presses are commercially available and include, for example Model #HPB-10 press from Greenerd Press and Machine Co., Inc. (Nashua, NH).
  • the polymeric materials may be in any form, including pellets, pre-formed sheets, and the like, when they are placed in the press.
  • the press may be heated to a temperature from about 95° C to about 230° C, in embodiments from about 130° C to about 225° C. Where the polymeric material is in pellet form, the pellets may be allowed to melt and spread across the plates of the press.
  • a suitable pressure may be applied to the polymer melt to form an article in accordance with the present disclosure having a desired thickness.
  • Suitable pressures may be from about 1 pounds per square inch (psi) to about 2500 psi, in embodiments from about 10 psi to about 100 psi.
  • the polymeric material may be subjected to this heat and temperature for a sufficient time to form an article of the present disclosure, in embodiments from about 5 seconds to about 10 minutes, in other embodiments from about 15 seconds to about 3 minutes.
  • Articles formed from pellets of a polymeric material utilizing a heat press as described herein may possess multi-directional orientation, thus eliminating fracture planes in the films thus formed.
  • a heat press may be utilized to form a film from a pre-formed sheet.
  • the polymer may be extruded from a general purpose extruder through a slit dye.
  • the thickness of the slit may vary from about 0.1 millimeters to about 25.4 millimeters, in some embodiments about 0.5 millimeters.
  • the resulting tape-like material may be too thick for certain applications, including for use as a buttress material in conjunction with a surgical stapler or a support material for a suture line.
  • the resulting tape may thus be placed on the plates of a heated hydraulic press as described above and heated to temperatures from about 95° C to about 230° C, in embodiments from about 108° C to about 115° C.
  • Extruded sheets may, in embodiments, possess less crystallinity than films formed from pellets, so less heat and pressure may be necessary to form suitable films therefrom.
  • shims or similar spacer devices may be placed on the plates of a heat press to ensure the resulting article, such as a film, possesses a desired thickness.
  • a die in the heat press having the general configuration of the desired final product, for example as a staple buttress or suture reinforcing line. After the polymer has been treated in the heat press, the resulting article may possess the configuration of the desired final product and thus require very little additional processing, if any.
  • a blown film process may be utilized to form an article of the present disclosure.
  • the polymer may be introduced into an extruder which contains a screw/barrel configuration and a jacket fitted with external heating elements to aid in melting the polymer.
  • the temperatures to which the barrel may be heated may vary depending upon the polymer utilized. In embodiments, the barrel may be heated to temperatures of from about 150° C to about 270° C, in embodiments from about 185° C to about 250° C. In other embodiments, different areas or sections of the barrel may be heated to different temperatures.
  • the polymer may be melted and transferred by the screw to the die from which it is extruded through a circular slit to form a tubular film having an initial diameter D 1 .
  • the tubular film may be expanded by compressed air or a compressed gas such as nitrogen, which enters the system through a die inlet port into the interior of the tubular film and has the effect of blowing up the diameter of the tubular film to a diameter D 2 .
  • D 1 may be from about 1 inch to about 2 inches, in some embodiments from about 1.25 inches to about 1.75 inches
  • D 2 may be from about 2 inches to about 6 inches, in some embodiments from about 3 inches to about 5 inches.
  • Means such as air rings may also be provided for directing air about the exterior of the extruded tubular film so as to provide quick and effective cooling and stabilization of the tube.
  • a heated or cooling mandrel or similar device may be used to heat/cool the tubular film, which may be used to control crystallization rates.
  • the sheets of film can then be cut or similarly treated to form a film possessing desired dimensions.
  • Films of varying thicknesses may be produced, including those having a thickness from about 0.001 inches to about 0.014 inches, in embodiments from about 0.002 inches to about 0.005 inches.
  • the resulting film may be annealed under a gas such as nitrogen for a period of time of from about 12 hours to about 24 hours, in embodiments from about 14 hours to about 22 hours, in embodiments about 18 hours, at temperatures of from about 40 ⁇ 5°C at the beginning of the annealing process to about 125 ⁇ 5°C for about the last six hours of the annealing process, to provide the film, which may be suitable for use as a buttress.
  • the film may be cooled to room temperature, in embodiments about 21 ⁇ 5°C, for a suitable period of time of from about 1 hour to about 10 hours, in embodiments from about 2 hours to about 8 hours.
  • the above heating and cooling may be varied depending upon the polymer utilized.
  • the above annealing treatment may be suitable, in embodiments, for films made of copolymers including copolymers of glycolide, dioxanone, and trimethylene carbonate, as well as copolymers including copolymers of glycolic acid and trimethylene carbonate.
  • films including copolymers of glycolide, caprolactone, trimethylene carbonate, and lactide may be annealed by heating at temperatures of from about 40 ⁇ 5°C to about 90 ⁇ 5°C for periods of time of from about 9 hours to about 12 hours, in embodiments from about 9.25 hours to about 11 hours, with temperatures of about 90 ⁇ 5°C for the last 8 hours of heating.
  • the film may be cooled to room temperature, in embodiments from about 21 ⁇ 5°C, for a period of time of from about 4 hours to about 8 hours.
  • the plates of a heated hydraulic press as described above may possess a texture which, in turn, will provide a textured surface to an article such as a film produced with the heated hydraulic press.
  • a separate material possessing a textured configuration such as a mesh, may be placed on the surface of a plate and the polymer pressed with the heated hydraulic press, so that the presence of the mesh imparts a textured surface to the resulting article.
  • the rollers as described above may similarly be textured to impart a textured surface to an article of the present disclosure.
  • Separate embossing rollers, plates, or similar devices may be utilized in some embodiments to provide texture to the surfaces of articles of the present disclosure. Such texture may be applied after an article has already been formed by placing the formed article in a press having a means for adding texture or passing it over rollers possessing such texture.
  • the article may be formed utilizing methods wherein texture is imparted to the article during the formation of the article itself.
  • a heat press possessing platens with a textured surface may be utilized to produce a tape, ribbon, sheet, or film and provide a textured surface to said article in a single step. The use of a single step to form an article and provide texture to a surface thereof may be desirable in some circumstances.
  • Articles thus produced with a textured surface may have desirable physical properties including an increase in the coefficient of friction as well as an improvement in the general appearance of the article surface.
  • Suitable texture patterns include, but are not limited to, random orientations of lines or other geometric shapes, words, pictures, logos, trademarks, combinations thereof, and the like.
  • an article of the present disclosure such as a buttress, may be combined with additional layers to form an article of the present disclosure.
  • Films, ribbons, tapes, sheets, buttresses, and the like formed in accordance with the present disclosure may have a thickness from about 0.0005 inches to about 0.014 inches, in embodiments from about 0.002 inches to about 0.005 inches, inclusive of any texture formed thereon.
  • the resulting ribbons, tapes, sheets, and/or films may be utilized as buttress materials for stapling devices utilized in wound closure.
  • the resulting ribbons, tapes, sheets, and/or films may be utilized as reinforcements for suture lines, either by being placed over a suture line and affixed thereto utilizing means within the purview of those skilled in the art, including adhesives, or by directly suturing the ribbon, tape, sheet, and/or film to tissue adjacent a wound so the ribbon, tape, sheet, and/or film is held in place over the wound by the suture.
  • the articles of the present disclosure are oriented in multiple directions or possess no orientation at all, fracture planes and the directionality of the orientation of an article are either eliminated or reduced.
  • the resulting articles are suitable for numerous uses, including use as a staple line reinforcement or a suture line reinforcement.
  • the multi-directional orientation of these materials will improve the tear resistance of the resulting films, ribbons, sheets, and/or tapes as the materials do not possess potential for forming propagating tears which may be formed with tapes having unidirectional orientation.
  • the films, ribbons, sheets, and/or tapes of the present disclosure may be used with any suture to reinforce the suture line and enhance the sealing of a wound.
  • the films, ribbons, sheets, and/or tapes of the present disclosure may be used as a buttress with any stapler utilized in a surgical procedure.
  • staplers include linear staplers, annular or circular staplers including those utilized in anastomosis procedures, and the like.
  • suitable staplers which may be utilized include, for example, those disclosed in U.S. Patent No. 3,490,675 , and U.S. Patent Application Publication Nos. 2006/0085034 , 2006/0135992 , and 2005/0245965 , the entire disclosures of each of which are incorporated by reference herein.
  • stapling apparatus which may be utilized with buttresses formed of the articles described herein includes laparoscopic staplers (see, e.g., U.S. Patent Nos. 6,330,965 and 6,241,139 , the entire disclosures of each of which are incorporated by reference herein), alternative stapling apparatus of the transverse anastomosis type for stapling a patient's mesentery (see, e.g., U.S. Patent No. 5,964,394 , the entire disclosure of which is incorporated by reference herein), and end-to-end anastomosis types for performing surgical anastomotic stapling with a circular cartridge and anvil mesentery (see, e.g., U.S.
  • Patent No. 5,915,616 the entire disclosure of which is incorporated by reference herein).
  • Other examples of endoscopic and/or laparoscopic surgical stapling devices which may be utilized with a buttress formed of an article of the present disclosure are disclosed in, for example, U.S. Patent No. 5,040,715 (Green, et al. ); U.S. Patent No. 5,307,976 (Olson, et al. ); U.S. Patent No. 5,312,023 (Green, et al. ); U.S. Patent No. 5,318,221 (Green, et al. ); U.S. Patent No. 5,326,013 (Green, et al. ); U.S. Patent No.
  • Buttresses formed of articles of the present disclosure may also be used in conjunction with instruments that apply two-part fasteners wherein a first part of the two-part fastener is stored in a cartridge or like member and can be fired and properly joined to a second part of the two-part fastener disposed in an anvil or like member.
  • instruments that apply two-part fasteners wherein a first part of the two-part fastener is stored in a cartridge or like member and can be fired and properly joined to a second part of the two-part fastener disposed in an anvil or like member.
  • a surgical stapling apparatus utilizing a buttress described herein may possess a staple cartridge containing at least one staple, an anvil having a staple forming surface, and a buttress of the present disclosure positioned adjacent the anvil or the cartridge.
  • Methods for closing a wound with such an apparatus are within the purview of those skilled in the art and may include, in embodiments, first enclosing tissue between the cartridge and anvil of the surgical stapling apparatus.
  • a buttress of the present disclosure may be positioned adjacent the cartridge, the anvil, or both. Staples may then be ejected from the cartridge to secure the buttress to tissue.
  • the buttress material may be releasably attached to the cartridge and/or the anvil component of a stapler in any manner capable of retaining the buttress in contact with the cartridge and/or the anvil prior to and during the stapling process, while allowing the buttress to be removed or released from the cartridge and/or the anvil following the penetration of the buttress by a surgical staple or other fastening device.
  • the buttress may be attached to the cartridge and/or the anvil using adhesives, sealants, glues, pins, tacks, tabs, clamps, channels, straps, protrusions and combinations thereof.
  • At least one bioactive agent may be combined with the buttress material or suture reinforcing material made with a ribbon, tape, sheet, and/or film of the present disclosure.
  • the article of the present disclosure can also serve as a vehicle for delivery of the bioactive agent.
  • bioactive agent as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, fragrance, or sealant.
  • a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, an anti-adhesive compound, a compound that seals or provides adhesive forces, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes.
  • the bioactive agent may be applied to the ribbon, tape, sheet, and/or film of the present disclosure in any suitable form of matter, e.g., films, powders, liquids, gels and the like.
  • bioactive agents examples include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
  • Anti-adhesive agents can be used to prevent adhesions from forming between the articles of the present disclosure and the surrounding tissues opposite the target tissue.
  • anti-adhesive agents may be used to prevent adhesions from forming between the articles of the present disclosure and any packaging material.
  • Some examples of these agents include, but are not limited to poly(vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols and combinations thereof.
  • Suitable antimicrobial agents which may be included as a bioactive agent with an article of the present disclosure include triclosan, also known as 2,4,4'-trichloro-2'-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin,
  • bioactive agents which may be included as a bioactive agent with an article of the present disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-mitotics; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g.
  • oxybutynin antitussives
  • bronchodilators cardiovascular agents such as coronary vasodilators and nitroglycerin
  • alkaloids analgesics
  • narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like
  • non-narcotics such as salicylates, aspirin, acetaminophen, naproxen, d-propoxyphene and the like
  • opioid receptor antagonists such as naltrexone and naloxone
  • anti-cancer agents telomerase inhibitors
  • anti-convulsants anti-emetics
  • antihistamines anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like
  • prostaglandins and cytotoxic drugs such as hormonal agents, hydrocortisone, pred
  • bioactive agents which may be included with an article of the present disclosure include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g.
  • lymphokines monokines, chemokines
  • blood clotting factors fibrin, thrombin, fibrinogen, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons ( ⁇ -IFN, ( ⁇ -IFN and ⁇ -IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as anti
  • bioactive agents which may be included with an article of the present disclosure may include those useful in the treatment of cancers.
  • agents include, for example, anti-mitotics, telomerase inhibitors, anti-proliferatives, anti-angiogenic drugs, antitumoral synthetic or biological compounds including antibodies, peptides, proteins, growth factors, and the like, and/or chemotherapeutic agents which may, in turn, include radiotherapeutic agents. Any such chemotherapeutic agent and/or radiotherapeutic agent may be included in an article of the present disclosure.
  • chemotherapeutic agents include, but are not limited to, cisplatin, carboplatin, paclitaxel, DHA-paclitaxel, docetaxel (Taxotere), doxetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, abraxane, 5-fluorouracil (5-FU), mitoxantrone, leucovorin, levamisole, daunorubicin, doxorubicin, methotrexate, adriamycin, bevacizumab, antibody and prodrug conjugates of these, HER-2/neu peptides, proteins, and related vaccines, combinations thereof, and the like.
  • radiotherapeutic agents which may be used include radioactive isotopes such as iodine 125, palladium 103, iridium 192, cesium 131, gold 198, yttrium 90 and phosphorus 32, combinations thereof, and the like.
  • polymers which impart some biological function such as phosphorylcholine or furanone containing polymers, may also be utilized.
  • bioactive agents such as radioactive isotopes may be applied to films of the present disclosure as seeds with the films thus being utilized for brachytherapy.
  • bioactive agents may be added to a film of the present disclosure.
  • a buttress or other medical article of the present disclosure may contain additional layers.
  • a bioactive agent may be incorporated in or applied to the surface of a single layer film, or additional layers may be applied thereto.
  • the film and bioactive agent could be applied to a backing material.
  • a barrier layer could be applied to the skin contacting surface of the film to help control the release of bioactive agents therefrom. Reservoirs containing the bioactive agent could also be constructed, with optional barrier layers thereover.
  • more than one layer of film, having different bioactive agents could be combined with optional backing layers and barrier layers, and thus have differential release of the two bioactive agents, with the agent in the layer closer to the skin released prior to the release of the agent in the layer further away from the skin.
  • bioactive agents such as the chemotherapeutic agents and/or radiotherapeutic agents described above, may be incorporated into a polymeric material utilized to form an article of the present disclosure, such as a film, by any method within the purview of those skilled in the art, including blending, mixing, emulsifying, suspending, layering, partitioning, coating, melt pressing, compressing, extruding, molding, combinations thereof, and the like.
  • the bioactive agent may be applied as a coating on at least a portion of a surface of an article of the present disclosure, such as a film, by any method or process within the purview of those skilled in the art, including dipping, spraying, ultrasonic spraying, vapor deposition, dusting, powder coating, rolling, brushing, immersion/wiping methods, melting, melt casting, electrostatic coating, electrospraying, combinations thereof, and the like.
  • the coating may contain macroparticles, microparticles, and/or nanoparticles, optionally with components such as drugs, and the like.
  • Drug/polymer coatings may be applied to one or multiple surfaces of the buttress. Some clinical applications may only desire one surface to be coated (for example, the surface between the buttress and tissue), while others may desire more than one surface to be coated. Moreover, the coating on a buttress may be the same coating applied to a staple utilized with the buttress, contained within the same cartridge of a stapler.
  • polymeric materials utilized to form a coating and/or particles within a coating may include lactones polyorthoesters, hydroxybutyrates, tyrosine carbonates, polymer drugs, anhydrides, degradable polyurethanes and related copolymers or chain extended polymers, alkylene oxide copolymers, vinyl polymers such as polyvinyl pyrrolidone, methacrylates, acrylates, phosphorylcholine containing vinyl polymers and copolymers, hydroxamate containing vinyl polymers and copolymers, natural polymers including polysaccharides such as hyaluronic acid, carboxymethyl cellulose, alginate, cellulose and its oxidized versions, fucans, and the like, proteins such as collagen and its oxidized versions, gelatin, elastin, albumin, fibrin, thrombin, fibrinogen, and the like, lipids and phospholipids (in embodiments, for the formation of liposomes), combinations thereof, and the like.
  • suitable polymeric materials for use as coatings and/or the formation of particles within coatings may include copolymers described above as suitable for use in forming the buttress materials.
  • Such materials may include, for example, homopolymers, copolymers, and/or blends possessing glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and various combinations of the foregoing.
  • a copolymer of glycolide and trimethylene carbonate may be utilized. Methods for forming such copolymers are within the purview of those skilled in the art and include, for example, the methods disclosed in U.S. Patent No.
  • Suitable copolymers of glycolide and trimethylene carbonate may possess glycolide in amounts from about 60% to about 75% by weight of the copolymer, in embodiments, from about 65% to about 70% by weight of the copolymer, with the trimethylene carbonate being present in amounts from about 25% to about 40% by weight of the copolymer, in embodiments from about 30% to about 35% by weight of the copolymer.
  • suitable copolymers may include copolymers of lactide and glycolide, with lactide present in an amount of from about 60% to about 80% by weight of the copolymer, in embodiments, from about 65% to about 75% by weight of the copolymer, with the glycolide being present in amounts from about 20% to about 40% by weight of the copolymer, in embodiments from about 25% to about 35% by weight of the copolymer.
  • suitable materials for forming articles of the present disclosure include, in embodiments, copolymers of glycolide, dioxanone and trimethylene carbonate.
  • Such materials may include, for example, copolymers possessing glycolide in amounts from about 55% to about 65% by weight of the copolymer, in embodiments from about 58% to about 62% by weight of the copolymer, in some embodiments about 60% by weight of the copolymer; dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, in embodiments from about 12% to about 16 % by weight of the copolymer, in some embodiments about 14% by weight of the copolymer; and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer, in embodiments from about 22% to about 30% by weight of the copolymer, in embodiments about 26% by weight of the copolymer.
  • a copolymer of glycolide, lactide, trimethylene carbonate and ⁇ -caprolactone may be utilized to form an article of the present disclosure.
  • Such materials may include, for example, a random copolymer possessing caprolactone in amounts from about 14% to about 20% by weight of the copolymer, in embodiments from about 16% to about 18% by weight of the copolymer, in some embodiments about 17% by weight of the copolymer; lactide in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in some embodiments about 7% by weight of the copolymer; trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in embodiments about 7% by weight of the copolymer; and glycolide in amounts from about 60% to about 78% by weight of the copolymer,
  • the coating may be in the form of continuous or discontinuous films.
  • Coatings/particles may also include single or multiple layers, some or all containing bioactive agents such as drugs.
  • outer layers may be used as barrier layers to slow/control the release of a drug, or as finishing layers to smooth or roughen surfaces of the buttress, depending upon the intended use.
  • a single and/or top coat may be used to modify the handling characteristics of the buttress, e.g., how slippery or sticky the buttress may be.
  • Coatings may be homogenous and phase compatible, or phase separated in some fashion.
  • the mode of coating application may vary the morphology as well, for example, dip or immersion coated samples may result in smooth laminar coatings, whereas ultrasonic spray coating for the same chemical formulation may result in a textured/rougher surface.
  • a film was produced from a polymer which included about 60% by weight glycolide, about 14% by weight dioxanone, and about 26% by weight trimethylene carbonate.
  • Polymer pellets were placed in a heated hydraulic press (Carver Laboratory Press, Model 2626). The press was heated to a temperature from about 125°C to about 165°C. The pellets were placed in the center of Teflon coated steel plates with steel shims to control the thickness of the resulting film. The pellets were allowed to melt and spread across the plates and a pressure of less than about 100 psi was applied to the polymer melt. The entire apparatus was crash cooled by running water through the plates. Films were obtained having a thickness of from about 0.002 inches to about 0.012 inches. The films had a multi-directional orientation.
  • a random copolymer possessing about 17% by weight caprolactone, about 7% by weight lactide, about 7% by weight trimethylene carbonate, and about 69% by weight glycolide was utilized to produce a film.
  • the copolymer was extruded from a 3 ⁇ 4 inch general purpose extruder through a slit dye.
  • a thick tape was produced.
  • the resulting tape was placed on Teflon coated steel plates in a hydraulic heat press as described above in Example 1, with the appropriate shims to produce a film having a desired thickness.
  • the heat press was heated to a temperature of about 105°C to about 120°C and a pressure of less than about 100 psi was applied.
  • films produced by this method had a thickness of from about 0.002 inches to about 0.012 inches. As the extruded film had less crystalline structure than the pellets of Example 1, a lower temperature could be used to make the polymer flow. The films had a multi-directional orientation.
  • a film was produced with the polymer described above in Example 2 using a blown film process.
  • Polymer pellets were introduced into an extruder (Randcastle Extrusion System, Inc., Cedar Grove, New Jersey) possessing a screw/barrel configuration and a jacket fitted with external heating elements.
  • the barrel had three zones held at three different temperatures, with zone 1 being closest to the portion of the barrel into which the polymer pellets were introduced, zone 2 being the mid-portion of the barrel, and zone 3 being the end of the barrel from which the polymer was extruded.
  • the length/diameter ratio of the barrel was 24 to 1, with a 3 ⁇ 4 inch screw inside the barrel.
  • a die having a diameter of about 1.25 inches was located at the end of the barrel through which the polymer melt was extruded.
  • the barrel temperature for zone 1 was about 344° F; for zone 2, from about 347° F to about 350° F; for zone 3, about 294° F; and for the adaptor between the barrel and the die, about 345° F.
  • the rate of spin of the screw was from about 80.5 revolutions per minute (rpm) to about 81.5 rpm, with the temperature at the die of from about 342° F to about 346° F.
  • the pressure in the barrel was from about 2000 psi to about 2069 psi, with the pressure at the die at from about 2079 psi to about 2196 psi.
  • the temperature of the polymer melt at extrusion was about 297° F.
  • the tubular film was expanded by compressed air which entered the system through an inlet into the interior of said tubular film.
  • the compressed air was utilized to expand the diameter of the tubular film to a diameter of about 3 inches.
  • An air ring was utilized to direct the air about the exterior of extruded tubular film so as to provide quick and effective cooling.
  • the thicknesses of the films produced were about 0.003 inches, 0.004 inches, 0.006 inches, and 0.008 inches.
  • the films thus produced had a multi-directional orientation.
  • Buttress coatings were made and applied utilizing a manual dip coating process. Briefly, from about 1% to about 6% (w/v) of paclitaxel was solubilized in a polymer solution of from about 1% to about 6% (w/v) of a glycolide/caprolactone polymer (about 10 % glycolide by weight and about 90% caprolactone by weight) using methylene chloride as a solvent.
  • Buttress discs (about 6mm in diameter) were punched from a production grade buttress made of a copolymer including about 60% by weight glycolide, about 14% by weight dioxanone, and about 26% by weight trimethylene carbonate, cleaned using an alcohol solvent wash mixture, and dried.
  • the discs were coated by direct immersion in the coating solution for approximately 30 to 60 seconds.
  • the discs were gently removed using micro-forceps and dried under a laminar flow hood for up to 2 hours. Subsequent drying was conducted under vacuum at ambient temperature overnight, i.e., from about 12 hours to about 20 hours.
  • HPLC high performance liquid chromatography
  • the 3 discs were removed from the original vial, rinsed with clean acetonitrile, and placed into a new 20 mL scintillation vial.
  • About 5 mL of methylene chloride was added to each vial and the vials were sonicated for about 1 hour. After sonication, the methylene chloride was evaporated under a stream of nitrogen and the paclitaxel was reconstituted in about 1 mL of acetonitrile. The samples were then filtered and injected through the HPLC column.
  • Paclitaxel concentrations were then measured with a Waters 2965 series HPLC (commercially available from Waters Corporation). A 20 ⁇ L from each sample was injected into a Phenomenex ODS-2 INERTSIL (5.0 ⁇ m, 150mm X 4.6, from Phenomenex) which was maintained at about 30°C. The sample runs were conducted for about 10 minutes, with a flow rate at 0.8mL/minute. The mobile phase included about 55% acetonitrile and 45% water (v/v). The paclitaxel was detected at a wavelength of about 230 nm with a photodiode array detector (Waters series 2996, commercially available from Waters Corporation).
  • a photodiode array detector Waters series 2996, commercially available from Waters Corporation.
  • a graph depicting the amount of paclitaxel in the buttresses is provided as Figure 1 .
  • a release medium including phosphate buffered saline (PBS) with about 0.1% of a polyethoxylated fatty acid ester of sorbitan (also referred to as polysorbates, commercially available as TWEENTM 80) (w/v) and about 0.5% sodium dodecylsulfate (SDS) (w/v) was prepared as follows. About 100 mL of 10X PBS concentrate was added to a 1 liter volumetric flask. The flask was filled to the line with Milli-Q water and stirred for about 15 minutes. To the solution, about 1 mL of TWEENTM 80was added and stirred with a magnetic stir bar until the TWEENTM 80was completely dissolved. Approximately 5 grams of sodium dodecylsulfate was then added and the solution was stirred for about 45 minutes. The pH of the solution was tested and found to be about 7.3.
  • PBS phosphate buffered saline
  • SDS sodium dodecylsulfate
  • the saturation concentration of paclitaxel in various release media was determined using the previously mentioned high pressure liquid chromatography method.
  • release media including PBS with about 0.1% TWEENTM 80 and 0.5% Sodium Dodecyl Sulfate described above, other media were similarly tested.
  • the additional media included PBS with about 0.1% by weight PLURAFAC® surfactant (commercially available from BASF), PBS with about 0.1% by weight TWEENTM 80, and PBS with about 0.8% by weight Dimethyl-b-Cyclodextrin.
  • the amount of paclitaxel released from the buttresses was determined by high performance liquid chromatography (HPLC), with the results summarized in Figure 3 .
  • Paclitaxel polymer coated buttresses were produced as in described in Example 4 above and evaluated for drug content and stability following sterilization. Non-sterilized materials were tested as controls. Samples were sterilized by exposure to ethylene oxide using the following parameters: 26 in Hg, 40 - 70% steam, 90 minute dwell time, 5.0 psi gas injection, 88°F to 108 °F, gas dwell time of from about 10.5 hours to about 14 hours at a gas concentration of 300 - 525 mg/L, and an air wash (8 pulses, air wash vacuum from about 20 to about 24 in Hg).
  • Figure 5 is a graph showing the buttress drug payload of paclitaxel over time following sterilization as determined using the HPLC method described above.
  • Tumor cell lines (colorectal, lung, neural) were chosen for use in this study due to the drastic morphological changes present in healthy, adherent cells versus cells undergoing cell death or those which are loosely adherent. Healthy, adherent tumor cells are typically elongated in morphology on adhesive substrates including the tissue culture polystyrene (TCPS) used in this study. In contrast, these tumor cells take on a small, rounded morphology on non-adhesive surfaces or when undergoing cell death.
  • TCPS tissue culture polystyrene
  • Tumor cells were plated into 96-well tissue culture polystyrene (TCPS) plates at a concentration of about 30,000 cells per mL in a volume of about 100 ⁇ L resulting in an initial tumor burden of about 3,000 cells.
  • Cell culture media included Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, Manassas, VA) with about 4 mM L-glutamine (added by manufacturer) and about 10% fetal bovine serum (FBS) (ATCC, Manassas, VA). Buttresses were immersed into the cultures within 1 hour of plating (1 staple per culture). Tumor cell cultures were incubated at 37°C and 5% CO 2 for 1, 3, and 7 days. Testing at particular timepoints was conducted as discussed below.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • MTT assay measures cell density by determining the ability of the cells to reduce MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide, from Sigma) into formazan. MTT is added to the cells at a final concentration of about 0.5 mg/ml, and then incubated with the cells for about 4 hours.
  • the absorbance of the converted dye was measured using a microplate reader spectrophotometer at a wavelength of from about 556 nm to about 600 nm with background subtraction at more than about 650 nm.
  • the measured absorbance correlated with the number of viable cells.
  • the results of the MTT assay showed that unadulterated drug was released at therapeutic levels and concentrations capable of inhibiting cell proliferation/viability.
  • the assay also showed no interaction between the drug and the coating material and that the drug was stable in the polymeric coating.

Abstract

Articles are provided having no orientation or a multi-directional orientation. Such articles may be in the form of films, ribbons, sheets, and/or tapes and may be utilized as buttresses with a surgical stapling apparatus or as reinforcing means for suture lines. The articles may be produced with a polymeric material having an agent, such as a chemotherapeutic agent or a radiotherapeutic agent, incorporated therein or applied as a coating thereon.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation in part of International Application No. PCT/US08/02978, filed March 5, 2008 , which, in turn, claims the benefit of and priority to U.S. Provisional Patent Application No. 60/905,532, filed March 6, 2007 , the entire disclosures of each of which are incorporated by reference herein.
  • BACKGROUND Technical Field
  • The present disclosure relates to articles of polymeric materials in tape, ribbon, sheet, and/or film configurations. These polymeric materials may be formed so that they possess no orientation or multi-directional orientation, which may enhance the integrity of the polymeric material when multidirectional forces are applied thereto. The polymeric materials of the present disclosure may be utilized in numerous applications including, in embodiments, as surgical buttresses or reinforcing tapes for staple or suture lines.
  • Background of Related Art
  • Films, ribbons, sheets, tapes, and the like which are made of polymeric materials are within the purview of those skilled in the art. Such materials may be produced by melting the polymeric material, extruding the material through a die, and then cooling the resulting material. This process may be very similar to methods utilized for forming filaments or films. The resulting material may be subsequently drawn at various draw ratios through a series of draw stations coupled with heated ovens or similar means in various configurations. This process may be coupled or de-coupled. The resulting drawn material, which may be in the form of a film, ribbon, sheet, tape, and the like, is usually highly oriented in a single direction, i.e., it possesses unidirectional orientation, linearly down its length (the direction in which it was drawn).
  • The straight pull tensile properties of these materials are usually measured in the same direction as their orientation. Such materials may thus possess great strength when pull forces are applied along the length of the material. While this unidirectional orientation may be desirable for certain uses, for example where similar extrusion, spinning and drawing methods are utilized to produce fibers such as sutures, filaments, and the like, such methods to produce tapes, ribbons, sheets, films, and the like may not be as desirable. This may be especially so where forces which are perpendicular to the unidirectional orientation of the material are applied, which may result in punctures, tears, or cuts in the polymeric material. In some cases, these tears may occur with the application of little force, which may be undesirable.
  • Surgical stapling devices have found widespread application in surgical operations where body tissue is joined or removed. While buttresses may be used in conjunction with stapling devices or sutures to enhance sealing of wounds, materials possessing a unidirectional orientation as described above may crack or tear with the application of small amounts of force. Moreover, when these materials are perforated by a staple or needle, propagating tears may form parallel to the unidirectional orientation, leading to premature material failure when forces are applied perpendicular to the orientation of the polymer.
  • Thus, it would be advantageous to provide a material for use with existing wound closure methods to enhance the sealing of a wound. Such materials may be utilized in conjunction with a surgical stapling device as well as sutures and other wound closure methods.
  • SUMMARY
  • According to an aspect of the present disclosure, a method is provided, including obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof; forming the polymeric material into an article that does not possess orientation in a single direction; contacting the polymeric material with at least one agent such as paclitaxel, DHA-paclitaxel, doxetaxel, abraxane, 5-fluorouracil (5-FU), mitoxantrone, daunorubicin, doxorubicin, cisplatin, carboplatin, methotrexate, bevacizumab, antibody and prodrug conjugates of these, HER-2/neu peptides, proteins, and related vaccines, iodine 125, palladium 103, iridium 192, cesium 131, gold 198, yttrium 90, phosphorus 32, and combinations thereof, and recovering the article.
  • In some embodiments, the polymeric material comprises a copolymer including glycolide in amounts from about 60% to about 75% by weight of the copolymer and trimethylene carbonate in amounts from about 25% to about 40% by weight of the copolymer.
  • In some embodiments, the polymeric material comprises a copolymer including glycolide in amounts from about 55% to about 65% by weight of the copolymer, dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer.
  • In some embodiments, the polymeric material comprises a copolymer including caprolactone in amounts from about 14% to about 20% by weight of the copolymer, lactide in amounts from about 4% to about 10% by weight of the copolymer, trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, and glycolide in amounts from about 60% to about 78% by weight of the copolymer.
  • In some embodiments, the step of forming the polymeric material into an article comprises forming an article selected from the group consisting of ribbons, tapes, sheets, and films.
  • In some embodiments, the step of forming the polymeric material into an article that does not possess orientation in a single direction results in an article possessing no orientation.
  • In some embodiments, the step of forming the polymeric material into an article that does not possess orientation in a single direction results in an article possessing multi-directional orientation.
  • In some embodiments, the step of forming the polymeric material into an article that does not possess orientation in a single direction occurs by a process selected from the group consisting of compression rollers, contoured rollers, heat pressing, blown film methods, and combinations thereof.
  • In some embodiments, the step of forming the polymeric material into an article that does not possess orientation in a single direction occurs by subjecting the polymeric material to a temperature of from about 95°C to about 230°C and a pressure of from about 1 psi to about 2500 psi, for a period of time from about 5 seconds to about 10 minutes.
  • In some embodiments, the step of forming the polymeric material into an article that does not possess orientation in a single direction occurs by introducing the polymeric material into a barrel heated to a temperature of from about 290° F to about 355° F, extruding the polymeric material through a die having a diameter of from about 1 inch to about 1.5 inches to produce a tubular film, expanding the tubular film to a diameter of from about 2 inches to about 4 inches, and flattening the tubular film to produce a film having a thickness from about 0.001 inches to about 0.014 inches.
  • In some embodiments, the method further includes forming a texture on at least one surface of the article.
  • In some embodiments, the article possesses a thickness of from about 0.0005 inches to about 0.014 inches.
  • In some embodiments, the article possesses a thickness of from about 0.002 inches to about 0.005 inches.
  • In some embodiment, a method is disclosed for producing a surgical staple buttress.
  • In some embodiment, a method is disclosed for producing a suture line reinforcement strip.
  • In an embodiment, there is provided a surgical stapling apparatus including a staple cartridge containing at least one staple; an anvil having a staple forming surface; and a buttress positioned adjacent the anvil or the cartridge, the buttress comprising an article produced by a method including obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof; forming the polymeric material into an article that does not possess orientation in a single direction; and recovering the article.
  • In an embodiment, there is provided a method of sealing a wound including enclosing tissue between a cartridge and an anvil of a surgical stapling apparatus, one of the cartridge or anvil having a buttress positioned adjacent thereto, wherein the buttress comprises an article produced by a method including obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof; forming the polymeric material into an article that does not possess orientation in a single direction; and recovering the article; and ejecting staples from the cartridge to secure the buttress to the tissue.
  • Polymeric articles are provided that do not possess orientation in a single direction, i.e., they may have no orientation or multi-directional orientation. The polymeric articles may be suitable for use in connection with a surgical stapling apparatus or similar wound closure devices to assist in the sealing of tissue to prevent the leakage of fluids and gases.
  • In embodiments, buttresses of the present disclosure may include multiple layers, optionally with coatings on at least a portion thereof. The coating may include a bioactive agent, in embodiments a chemotherapeutic agent. Where a bioactive agent is present, the buttress may thus be utilized to deliver bioactive agents such as chemotherapeutic agents and other drugs.
  • BRIEF DESCRIPTION OF THE FIGURES
  • Various embodiments of the present disclosure will be described herein below with reference to the figures wherein:
    • Figure 1 is a graph depicting the amount of paclitaxel loaded in a buttress sample in accordance with the present disclosure;
    • Figure 2A is a calibration curve showing retention of paclitaxel in a buttress of the present disclosure;
    • Figure 2B is a close-up of some of the peaks of the calibration curve in Figure 2A;
    • Figure 3 is a graph depicting the cumulative release of paclitaxel from a buttress of the present disclosure;
    • Figure 4 is a graph depicting the cumulative release of paclitaxel from a buttress of the present disclosure; and
    • Figure 5 is a graph showing average paclitaxel payload over time for sterilized and non-sterilized buttresses of the present disclosure.
    DETAILED DESCRIPTION
  • Polymeric articles in the form of tapes, ribbons, sheets, films, and the like are provided in accordance with the present disclosure made of materials that are not highly oriented in a single direction, i.e., they may have no orientation or multi-directional orientation. Where the materials possess multi-directional orientation, the materials may be more oriented in one direction, with some orientation in a different direction, in embodiments a perpendicular direction, or the materials may possess omni-directional orientation, i.e., being oriented in all directions. In embodiments, the polymeric materials may be utilized to form buttresses or similar materials for use in conjunction with wound closure devices such as staplers and sutures to enhance wound closure.
  • Suitable materials for use in forming the polymeric tapes, ribbons, sheets, and films may include any biocompatible material. Thus, the polymeric articles may be formed from a natural material or a synthetic material. The polymeric article may be bioabsorbable or non-bioabsorbable. It should of course be understood that any combination of natural, synthetic, bioabsorbable and/or non-bioabsorbable materials may be used. Some non-limiting examples of materials which may be used to form articles of the present disclosure include, but are not limited to, poly(lactic acid), poly (glycolic acid), poly (hydroxybutyrate), poly(phosphazine), polyesters, polyethylene glycols, polyethylene oxides, polyacrylamides, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly(ether-esters), polyalkylene oxalates, polyamides, poly(iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes and copolymers, block copolymers, homopolymers, blends and combinations thereof.
  • In embodiments, suitable materials which may be utilized to form the articles of the present disclosure such as tapes, ribbons, sheets, films, and the like, include homopolymers, copolymers, and/or blends possessing glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and various combinations of the foregoing. For example, in some embodiments, a copolymer of glycolide and trimethylene carbonate may be utilized. Methods for forming such copolymers are within the purview of those skilled in the art and include, for example, the methods disclosed in U.S. Patent No. 4,300,565 , the entire disclosure of which is incorporated by reference herein. Suitable copolymers of glycolide and trimethylene carbonate may possess glycolide in amounts from about 60% to about 75% by weight of the copolymer, in embodiments, from about 65% to about 70% by weight of the copolymer, with the trimethylene carbonate being present in amounts from about 25% to about 40% by weight of the copolymer, in embodiments from about 30% to about 35% by weight of the copolymer.
  • Other suitable materials for forming articles of the present disclosure include, in embodiments, copolymers of glycolide, dioxanone and trimethylene carbonate. Such materials may include, for example, copolymers possessing glycolide in amounts from about 55% to about 65% by weight of the copolymer, in embodiments from about 58% to about 62% by weight of the copolymer, in some embodiments about 60% by weight of the copolymer; dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, in embodiments from about 12% to about 16 % by weight of the copolymer, in some embodiments about 14% by weight of the copolymer; and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer, in embodiments from about 22% to about 30% by weight of the copolymer, in embodiments about 26% by weight of the copolymer.
  • In other embodiments, a copolymer of glycolide, lactide, trimethylene carbonate and ε-caprolactone may be utilized to form an article of the present disclosure. Such materials may include, for example, a random copolymer possessing caprolactone in amounts from about 14% to about 20% by weight of the copolymer, in embodiments from about 16% to about 18% by weight of the copolymer, in some embodiments about 17% by weight of the copolymer; lactide in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in some embodiments about 7% by weight of the copolymer; trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in embodiments about 7% by weight of the copolymer; and glycolide in amounts from about 60% to about 78% by weight of the copolymer, in embodiments from about 66% to about 72% by weight of the copolymer, in embodiments about 69% by weight of the copolymer.
  • Methods for forming such copolymers are within the purview of those skilled in the art. In embodiments, the individual monomers may be combined in the presence of an initiator, such as diethylene glycol, and a catalyst, such as stannous octoate. The materials may be combined for a suitable period of time from about 4 hours to about 8 hours, in embodiments from about 5 hours to about 7 hours, in other embodiments for about 6 hours. In some cases the mixture may be held under an inert atmosphere, such as under nitrogen gas. The mixture may then heated to a temperature from about 80° C to about 120° C, in embodiments from about 90° C to about 110° C, in some cases to about 100° C, for a suitable period of time of from about 5 minutes to about 30 minutes, in embodiments from about 10 minutes to about 20 minutes, in other embodiments for about 15 minutes. The reaction mixture may then be heated to a temperature from about 130° C to about 170° C, in embodiments from about 140° C to about 160° C, in embodiments to about 150° C, for a suitable period of time of from about 5 minutes to about 30 minutes, in embodiments from about 10 minutes to about 20 minutes, in other embodiments for about 15 minutes. The mixture may then be heated to a temperature of from about 170° C to about 190° C, in embodiments to about 180° C, and allowed to polymerize for a period of from about 14 to about 24 hours, in embodiments from about 16 to about 20 hours, in some embodiments about 18 hours.
  • Once the polymeric material has been obtained, methods for forming articles such as ribbons, tapes, sheets, and/or films from these materials include, but are not limited to, the use of compression rollers, the use of contoured rollers, heat pressing, blown film methods, combinations thereof, and the like.
  • In a compression roller system, the polymer is melted and extruded from a die of a suitable thickness. As the polymer melt exits the extruder die it may be fed through two rollers opposite each other which press against each other and any film passing there between with sufficient pressure to compress the material to the desired thickness. The rollers can both be cooled, both heated, or have one cooled and one heated. Any method within the purview of those skilled in the art may be utilized to heat and/or cool the rollers. Such methods include, for example, induction, jacketed, air heated, air cooled, contained in an oven or refrigerator, and the like. To reduce unidirectional orientation within the polymer melt, the compressing rollers may rotate at about the same or close to the same speed as collection rollers used to advance the material through the system and match the rate of extrusion of material exiting the die. After passing through a compression roller system, the resulting article may be in a tape, ribbon, sheet, film, or similar configuration.
  • In other embodiments, contoured rollers may be utilized instead of compression rollers to form the articles of the present disclosure. Current draw station rollers may be cylindrical and draw spun-drawn polymeric material exiting an extruder in one direction leading to the unidirectional orientation of the resulting film. The use of laterally oriented non-cylindrical (e.g., spherical, football-shaped, elliptical) rollers between the draw stations may stretch the film laterally as it moves through the drawing process, thus resulting in both longitudinal and latitudinal orientation of the resulting film. The multidirectional stretching and resulting multidirectional orientation may minimize or avoid the formation of fracture planes in the resulting material.
  • In yet other embodiments, articles of the present disclosure, including films, may be formed utilizing a heat press, sometimes referred to herein as a heated hydraulic press. Suitable heat presses are commercially available and include, for example Model #HPB-10 press from Greenerd Press and Machine Co., Inc. (Nashua, NH). The polymeric materials may be in any form, including pellets, pre-formed sheets, and the like, when they are placed in the press. The press may be heated to a temperature from about 95° C to about 230° C, in embodiments from about 130° C to about 225° C. Where the polymeric material is in pellet form, the pellets may be allowed to melt and spread across the plates of the press. A suitable pressure may be applied to the polymer melt to form an article in accordance with the present disclosure having a desired thickness. Suitable pressures may be from about 1 pounds per square inch (psi) to about 2500 psi, in embodiments from about 10 psi to about 100 psi. The polymeric material may be subjected to this heat and temperature for a sufficient time to form an article of the present disclosure, in embodiments from about 5 seconds to about 10 minutes, in other embodiments from about 15 seconds to about 3 minutes. Articles formed from pellets of a polymeric material utilizing a heat press as described herein may possess multi-directional orientation, thus eliminating fracture planes in the films thus formed.
  • In other embodiments, a heat press may be utilized to form a film from a pre-formed sheet. For example, the polymer may be extruded from a general purpose extruder through a slit dye. The thickness of the slit may vary from about 0.1 millimeters to about 25.4 millimeters, in some embodiments about 0.5 millimeters. The resulting tape-like material may be too thick for certain applications, including for use as a buttress material in conjunction with a surgical stapler or a support material for a suture line. The resulting tape may thus be placed on the plates of a heated hydraulic press as described above and heated to temperatures from about 95° C to about 230° C, in embodiments from about 108° C to about 115° C. Pressure may then be applied from about 25 psi to about 2000 psi, in embodiments from about 50 psi to about 100 psi. Extruded sheets may, in embodiments, possess less crystallinity than films formed from pellets, so less heat and pressure may be necessary to form suitable films therefrom.
  • In some embodiments, shims or similar spacer devices may be placed on the plates of a heat press to ensure the resulting article, such as a film, possesses a desired thickness. In addition, it may be desirable to utilize a die in the heat press having the general configuration of the desired final product, for example as a staple buttress or suture reinforcing line. After the polymer has been treated in the heat press, the resulting article may possess the configuration of the desired final product and thus require very little additional processing, if any.
  • In yet other embodiments, a blown film process may be utilized to form an article of the present disclosure. The polymer may be introduced into an extruder which contains a screw/barrel configuration and a jacket fitted with external heating elements to aid in melting the polymer. As would be readily appreciated by one skilled in the art, the temperatures to which the barrel may be heated may vary depending upon the polymer utilized. In embodiments, the barrel may be heated to temperatures of from about 150° C to about 270° C, in embodiments from about 185° C to about 250° C. In other embodiments, different areas or sections of the barrel may be heated to different temperatures.
  • The polymer may be melted and transferred by the screw to the die from which it is extruded through a circular slit to form a tubular film having an initial diameter D1. The tubular film may be expanded by compressed air or a compressed gas such as nitrogen, which enters the system through a die inlet port into the interior of the tubular film and has the effect of blowing up the diameter of the tubular film to a diameter D2. In some embodiments, D1 may be from about 1 inch to about 2 inches, in some embodiments from about 1.25 inches to about 1.75 inches, and D2 may be from about 2 inches to about 6 inches, in some embodiments from about 3 inches to about 5 inches. Means such as air rings may also be provided for directing air about the exterior of the extruded tubular film so as to provide quick and effective cooling and stabilization of the tube. In some embodiments a heated or cooling mandrel or similar device may be used to heat/cool the tubular film, which may be used to control crystallization rates. After a short distance, during which the film is allowed to completely cool and harden, it is collapsed by means of a driven nip roller system, which flattens the material into a sheet of double-thickness film which can, in embodiments, be separated into two sheets of film. The sheets of film can then be cut or similarly treated to form a film possessing desired dimensions. Films of varying thicknesses may be produced, including those having a thickness from about 0.001 inches to about 0.014 inches, in embodiments from about 0.002 inches to about 0.005 inches.
  • In embodiments, the resulting film may be annealed under a gas such as nitrogen for a period of time of from about 12 hours to about 24 hours, in embodiments from about 14 hours to about 22 hours, in embodiments about 18 hours, at temperatures of from about 40 ± 5°C at the beginning of the annealing process to about 125 ± 5°C for about the last six hours of the annealing process, to provide the film, which may be suitable for use as a buttress. After the above annealing treatment, the film may be cooled to room temperature, in embodiments about 21 ± 5°C, for a suitable period of time of from about 1 hour to about 10 hours, in embodiments from about 2 hours to about 8 hours. The above heating and cooling may be varied depending upon the polymer utilized. For example, the above annealing treatment may be suitable, in embodiments, for films made of copolymers including copolymers of glycolide, dioxanone, and trimethylene carbonate, as well as copolymers including copolymers of glycolic acid and trimethylene carbonate.
  • Other materials, however, may be subjected to other treatments. For example, films including copolymers of glycolide, caprolactone, trimethylene carbonate, and lactide may be annealed by heating at temperatures of from about 40 ± 5°C to about 90 ± 5°C for periods of time of from about 9 hours to about 12 hours, in embodiments from about 9.25 hours to about 11 hours, with temperatures of about 90 ± 5°C for the last 8 hours of heating. After the above annealing treatment, the film may be cooled to room temperature, in embodiments from about 21 ± 5°C, for a period of time of from about 4 hours to about 8 hours.
  • In embodiments, it may be desirable to provide an article of the present disclosure with a textured surface. For example, the plates of a heated hydraulic press as described above may possess a texture which, in turn, will provide a textured surface to an article such as a film produced with the heated hydraulic press. In other embodiments a separate material possessing a textured configuration, such as a mesh, may be placed on the surface of a plate and the polymer pressed with the heated hydraulic press, so that the presence of the mesh imparts a textured surface to the resulting article. In other embodiments, the rollers as described above may similarly be textured to impart a textured surface to an article of the present disclosure. Separate embossing rollers, plates, or similar devices may be utilized in some embodiments to provide texture to the surfaces of articles of the present disclosure. Such texture may be applied after an article has already been formed by placing the formed article in a press having a means for adding texture or passing it over rollers possessing such texture. In other embodiments the article may be formed utilizing methods wherein texture is imparted to the article during the formation of the article itself. Thus, for example, a heat press possessing platens with a textured surface may be utilized to produce a tape, ribbon, sheet, or film and provide a textured surface to said article in a single step. The use of a single step to form an article and provide texture to a surface thereof may be desirable in some circumstances.
  • Articles thus produced with a textured surface may have desirable physical properties including an increase in the coefficient of friction as well as an improvement in the general appearance of the article surface. Suitable texture patterns include, but are not limited to, random orientations of lines or other geometric shapes, words, pictures, logos, trademarks, combinations thereof, and the like.
  • In other embodiments, an article of the present disclosure, such as a buttress, may be combined with additional layers to form an article of the present disclosure.
  • Films, ribbons, tapes, sheets, buttresses, and the like formed in accordance with the present disclosure may have a thickness from about 0.0005 inches to about 0.014 inches, in embodiments from about 0.002 inches to about 0.005 inches, inclusive of any texture formed thereon.
  • As noted above, in embodiments, the resulting ribbons, tapes, sheets, and/or films may be utilized as buttress materials for stapling devices utilized in wound closure. Similarly, the resulting ribbons, tapes, sheets, and/or films may be utilized as reinforcements for suture lines, either by being placed over a suture line and affixed thereto utilizing means within the purview of those skilled in the art, including adhesives, or by directly suturing the ribbon, tape, sheet, and/or film to tissue adjacent a wound so the ribbon, tape, sheet, and/or film is held in place over the wound by the suture.
  • As the articles of the present disclosure are oriented in multiple directions or possess no orientation at all, fracture planes and the directionality of the orientation of an article are either eliminated or reduced. The resulting articles are suitable for numerous uses, including use as a staple line reinforcement or a suture line reinforcement. The multi-directional orientation of these materials will improve the tear resistance of the resulting films, ribbons, sheets, and/or tapes as the materials do not possess potential for forming propagating tears which may be formed with tapes having unidirectional orientation.
  • For example, the films, ribbons, sheets, and/or tapes of the present disclosure may be used with any suture to reinforce the suture line and enhance the sealing of a wound. Moreover, the films, ribbons, sheets, and/or tapes of the present disclosure may be used as a buttress with any stapler utilized in a surgical procedure. Such staplers include linear staplers, annular or circular staplers including those utilized in anastomosis procedures, and the like. Examples of suitable staplers which may be utilized include, for example, those disclosed in U.S. Patent No. 3,490,675 , and U.S. Patent Application Publication Nos. 2006/0085034 , 2006/0135992 , and 2005/0245965 , the entire disclosures of each of which are incorporated by reference herein.
  • Other examples of stapling apparatus which may be utilized with buttresses formed of the articles described herein includes laparoscopic staplers (see, e.g., U.S. Patent Nos. 6,330,965 and 6,241,139 , the entire disclosures of each of which are incorporated by reference herein), alternative stapling apparatus of the transverse anastomosis type for stapling a patient's mesentery (see, e.g., U.S. Patent No. 5,964,394 , the entire disclosure of which is incorporated by reference herein), and end-to-end anastomosis types for performing surgical anastomotic stapling with a circular cartridge and anvil mesentery (see, e.g., U.S. Patent No. 5,915,616 , the entire disclosure of which is incorporated by reference herein). Other examples of endoscopic and/or laparoscopic surgical stapling devices which may be utilized with a buttress formed of an article of the present disclosure are disclosed in, for example, U.S. Patent No. 5,040,715 (Green, et al. ); U.S. Patent No. 5,307,976 (Olson, et al. ); U.S. Patent No. 5,312,023 (Green, et al. ); U.S. Patent No. 5,318,221 (Green, et al. ); U.S. Patent No. 5,326,013 (Green, et al. ); U.S. Patent No. 5,332,142 (Robinson, et al. ); and U.S. Patent No. 6,241,139 (Milliman et al. ), the entire disclosures of each of which are incorporated by reference herein. Commercially available staplers which may be utilized with a buttress formed of an article of the present disclosure include, but are not limited to, those available from Tyco Healthcare Group, LP under the name Multifire ENDO GIA™ 30 and Multifire ENDO GIA™ 60 instruments.
  • Buttresses formed of articles of the present disclosure may also be used in conjunction with instruments that apply two-part fasteners wherein a first part of the two-part fastener is stored in a cartridge or like member and can be fired and properly joined to a second part of the two-part fastener disposed in an anvil or like member. Those skilled in the art having read the present disclosure will readily envision how to adapt the present buttresses for use in connection with such apparatus and also envision other surgical apparatus with which the buttresses described herein may be used.
  • At a minimum, a surgical stapling apparatus utilizing a buttress described herein may possess a staple cartridge containing at least one staple, an anvil having a staple forming surface, and a buttress of the present disclosure positioned adjacent the anvil or the cartridge. Methods for closing a wound with such an apparatus are within the purview of those skilled in the art and may include, in embodiments, first enclosing tissue between the cartridge and anvil of the surgical stapling apparatus. A buttress of the present disclosure may be positioned adjacent the cartridge, the anvil, or both. Staples may then be ejected from the cartridge to secure the buttress to tissue.
  • Where utilized with a surgical stapler, it is envisioned that the buttress material may be releasably attached to the cartridge and/or the anvil component of a stapler in any manner capable of retaining the buttress in contact with the cartridge and/or the anvil prior to and during the stapling process, while allowing the buttress to be removed or released from the cartridge and/or the anvil following the penetration of the buttress by a surgical staple or other fastening device. For example, the buttress may be attached to the cartridge and/or the anvil using adhesives, sealants, glues, pins, tacks, tabs, clamps, channels, straps, protrusions and combinations thereof.
  • In some embodiments, at least one bioactive agent may be combined with the buttress material or suture reinforcing material made with a ribbon, tape, sheet, and/or film of the present disclosure. In these embodiments, the article of the present disclosure can also serve as a vehicle for delivery of the bioactive agent. The term "bioactive agent", as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, fragrance, or sealant. Alternatively a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, an anti-adhesive compound, a compound that seals or provides adhesive forces, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes. It is envisioned that the bioactive agent may be applied to the ribbon, tape, sheet, and/or film of the present disclosure in any suitable form of matter, e.g., films, powders, liquids, gels and the like. Examples of classes of bioactive agents which may be utilized in accordance with the present disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
  • Anti-adhesive agents can be used to prevent adhesions from forming between the articles of the present disclosure and the surrounding tissues opposite the target tissue. In addition, anti-adhesive agents may be used to prevent adhesions from forming between the articles of the present disclosure and any packaging material. Some examples of these agents include, but are not limited to poly(vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols and combinations thereof.
  • Suitable antimicrobial agents which may be included as a bioactive agent with an article of the present disclosure include triclosan, also known as 2,4,4'-trichloro-2'-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol 9, fusidic acid, cephalosporins, brominated furanones, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent with an article of the present disclosure.
  • Other bioactive agents which may be included as a bioactive agent with an article of the present disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-mitotics; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, naproxen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; telomerase inhibitors; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antibiotics; antifungals; anti-virals; anticoagulants; antiproliferatives; anti-angiogenic drugs; polymer drugs; bioactive functionalized polymers including polymers possessing phosphoryl cholines and/or furanones; anticonvulsants; antidepressants; antihistamines; and immunological agents.
  • Other examples of suitable bioactive agents which may be included with an article of the present disclosure include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, fibrin, thrombin, fibrinogen, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β-IFN, (α-IFN and γ-IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; biologic complexes; metal ion complexes; polynucleotides; and ribozymes.
  • In embodiments, bioactive agents which may be included with an article of the present disclosure may include those useful in the treatment of cancers. Such agents include, for example, anti-mitotics, telomerase inhibitors, anti-proliferatives, anti-angiogenic drugs, antitumoral synthetic or biological compounds including antibodies, peptides, proteins, growth factors, and the like, and/or chemotherapeutic agents which may, in turn, include radiotherapeutic agents. Any such chemotherapeutic agent and/or radiotherapeutic agent may be included in an article of the present disclosure. Examples of such chemotherapeutic agents include, but are not limited to, cisplatin, carboplatin, paclitaxel, DHA-paclitaxel, docetaxel (Taxotere), doxetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, abraxane, 5-fluorouracil (5-FU), mitoxantrone, leucovorin, levamisole, daunorubicin, doxorubicin, methotrexate, adriamycin, bevacizumab, antibody and prodrug conjugates of these, HER-2/neu peptides, proteins, and related vaccines, combinations thereof, and the like.
  • Suitable radiotherapeutic agents which may be used include radioactive isotopes such as iodine 125, palladium 103, iridium 192, cesium 131, gold 198, yttrium 90 and phosphorus 32, combinations thereof, and the like. In embodiments polymers which impart some biological function, such as phosphorylcholine or furanone containing polymers, may also be utilized.
  • In embodiments, bioactive agents such as radioactive isotopes may be applied to films of the present disclosure as seeds with the films thus being utilized for brachytherapy.
  • As noted above, in embodiments combinations of any of the foregoing bioactive agents may be added to a film of the present disclosure.
  • As noted above, in embodiments a buttress or other medical article of the present disclosure may contain additional layers. Thus, a bioactive agent may be incorporated in or applied to the surface of a single layer film, or additional layers may be applied thereto. For example, the film and bioactive agent could be applied to a backing material. In other embodiments, a barrier layer could be applied to the skin contacting surface of the film to help control the release of bioactive agents therefrom. Reservoirs containing the bioactive agent could also be constructed, with optional barrier layers thereover. Additionally, more than one layer of film, having different bioactive agents, could be combined with optional backing layers and barrier layers, and thus have differential release of the two bioactive agents, with the agent in the layer closer to the skin released prior to the release of the agent in the layer further away from the skin.
  • The bioactive agents, such as the chemotherapeutic agents and/or radiotherapeutic agents described above, may be incorporated into a polymeric material utilized to form an article of the present disclosure, such as a film, by any method within the purview of those skilled in the art, including blending, mixing, emulsifying, suspending, layering, partitioning, coating, melt pressing, compressing, extruding, molding, combinations thereof, and the like. In other embodiments, the bioactive agent may be applied as a coating on at least a portion of a surface of an article of the present disclosure, such as a film, by any method or process within the purview of those skilled in the art, including dipping, spraying, ultrasonic spraying, vapor deposition, dusting, powder coating, rolling, brushing, immersion/wiping methods, melting, melt casting, electrostatic coating, electrospraying, combinations thereof, and the like. In other embodiments, the coating may contain macroparticles, microparticles, and/or nanoparticles, optionally with components such as drugs, and the like.
  • Drug/polymer coatings may be applied to one or multiple surfaces of the buttress. Some clinical applications may only desire one surface to be coated (for example, the surface between the buttress and tissue), while others may desire more than one surface to be coated. Moreover, the coating on a buttress may be the same coating applied to a staple utilized with the buttress, contained within the same cartridge of a stapler.
  • In embodiments, polymeric materials utilized to form a coating and/or particles within a coating may include lactones polyorthoesters, hydroxybutyrates, tyrosine carbonates, polymer drugs, anhydrides, degradable polyurethanes and related copolymers or chain extended polymers, alkylene oxide copolymers, vinyl polymers such as polyvinyl pyrrolidone, methacrylates, acrylates, phosphorylcholine containing vinyl polymers and copolymers, hydroxamate containing vinyl polymers and copolymers, natural polymers including polysaccharides such as hyaluronic acid, carboxymethyl cellulose, alginate, cellulose and its oxidized versions, fucans, and the like, proteins such as collagen and its oxidized versions, gelatin, elastin, albumin, fibrin, thrombin, fibrinogen, and the like, lipids and phospholipids (in embodiments, for the formation of liposomes), combinations thereof, and the like.
  • In embodiments, suitable polymeric materials for use as coatings and/or the formation of particles within coatings may include copolymers described above as suitable for use in forming the buttress materials. Such materials may include, for example, homopolymers, copolymers, and/or blends possessing glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and various combinations of the foregoing. For example, in some embodiments, a copolymer of glycolide and trimethylene carbonate may be utilized. Methods for forming such copolymers are within the purview of those skilled in the art and include, for example, the methods disclosed in U.S. Patent No. 4,300,565 , the entire disclosure of which is incorporated by reference herein. Suitable copolymers of glycolide and trimethylene carbonate may possess glycolide in amounts from about 60% to about 75% by weight of the copolymer, in embodiments, from about 65% to about 70% by weight of the copolymer, with the trimethylene carbonate being present in amounts from about 25% to about 40% by weight of the copolymer, in embodiments from about 30% to about 35% by weight of the copolymer.
  • Other suitable copolymers may include copolymers of lactide and glycolide, with lactide present in an amount of from about 60% to about 80% by weight of the copolymer, in embodiments, from about 65% to about 75% by weight of the copolymer, with the glycolide being present in amounts from about 20% to about 40% by weight of the copolymer, in embodiments from about 25% to about 35% by weight of the copolymer.
  • Other suitable materials for forming articles of the present disclosure include, in embodiments, copolymers of glycolide, dioxanone and trimethylene carbonate. Such materials may include, for example, copolymers possessing glycolide in amounts from about 55% to about 65% by weight of the copolymer, in embodiments from about 58% to about 62% by weight of the copolymer, in some embodiments about 60% by weight of the copolymer; dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, in embodiments from about 12% to about 16 % by weight of the copolymer, in some embodiments about 14% by weight of the copolymer; and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer, in embodiments from about 22% to about 30% by weight of the copolymer, in embodiments about 26% by weight of the copolymer.
  • In other embodiments, a copolymer of glycolide, lactide, trimethylene carbonate and ε-caprolactone may be utilized to form an article of the present disclosure. Such materials may include, for example, a random copolymer possessing caprolactone in amounts from about 14% to about 20% by weight of the copolymer, in embodiments from about 16% to about 18% by weight of the copolymer, in some embodiments about 17% by weight of the copolymer; lactide in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in some embodiments about 7% by weight of the copolymer; trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, in embodiments from about 6% to about 8% by weight of the copolymer, in embodiments about 7% by weight of the copolymer; and glycolide in amounts from about 60% to about 78% by weight of the copolymer, in embodiments from about 66% to about 72% by weight of the copolymer, in embodiments about 69% by weight of the copolymer.
  • In embodiments, the coating may be in the form of continuous or discontinuous films. Coatings/particles may also include single or multiple layers, some or all containing bioactive agents such as drugs. In embodiments, outer layers may be used as barrier layers to slow/control the release of a drug, or as finishing layers to smooth or roughen surfaces of the buttress, depending upon the intended use. In other embodiments, a single and/or top coat may be used to modify the handling characteristics of the buttress, e.g., how slippery or sticky the buttress may be.
  • Coatings may be homogenous and phase compatible, or phase separated in some fashion. The mode of coating application may vary the morphology as well, for example, dip or immersion coated samples may result in smooth laminar coatings, whereas ultrasonic spray coating for the same chemical formulation may result in a textured/rougher surface.
  • The following Examples are being submitted to illustrate embodiments of the present disclosure. These Examples are intended as illustrative only and are not intended to limit the scope of the present disclosure. Also, parts and percentages are by weight unless otherwise indicated.
  • EXAMPLE 1
  • A film was produced from a polymer which included about 60% by weight glycolide, about 14% by weight dioxanone, and about 26% by weight trimethylene carbonate. Polymer pellets were placed in a heated hydraulic press (Carver Laboratory Press, Model 2626). The press was heated to a temperature from about 125°C to about 165°C. The pellets were placed in the center of Teflon coated steel plates with steel shims to control the thickness of the resulting film. The pellets were allowed to melt and spread across the plates and a pressure of less than about 100 psi was applied to the polymer melt. The entire apparatus was crash cooled by running water through the plates. Films were obtained having a thickness of from about 0.002 inches to about 0.012 inches. The films had a multi-directional orientation.
  • EXAMPLE 2
  • A random copolymer possessing about 17% by weight caprolactone, about 7% by weight lactide, about 7% by weight trimethylene carbonate, and about 69% by weight glycolide was utilized to produce a film. The copolymer was extruded from a ¾ inch general purpose extruder through a slit dye. A thick tape was produced. The resulting tape was placed on Teflon coated steel plates in a hydraulic heat press as described above in Example 1, with the appropriate shims to produce a film having a desired thickness. The heat press was heated to a temperature of about 105°C to about 120°C and a pressure of less than about 100 psi was applied. Similar to the films produced in Example 1 utilizing pellets, films produced by this method had a thickness of from about 0.002 inches to about 0.012 inches. As the extruded film had less crystalline structure than the pellets of Example 1, a lower temperature could be used to make the polymer flow. The films had a multi-directional orientation.
  • EXAMPLE 3
  • A film was produced with the polymer described above in Example 2 using a blown film process. Polymer pellets were introduced into an extruder (Randcastle Extrusion System, Inc., Cedar Grove, New Jersey) possessing a screw/barrel configuration and a jacket fitted with external heating elements. The barrel had three zones held at three different temperatures, with zone 1 being closest to the portion of the barrel into which the polymer pellets were introduced, zone 2 being the mid-portion of the barrel, and zone 3 being the end of the barrel from which the polymer was extruded. The length/diameter ratio of the barrel was 24 to 1, with a ¾ inch screw inside the barrel. A die having a diameter of about 1.25 inches was located at the end of the barrel through which the polymer melt was extruded.
  • The barrel temperature for zone 1 was about 344° F; for zone 2, from about 347° F to about 350° F; for zone 3, about 294° F; and for the adaptor between the barrel and the die, about 345° F. The rate of spin of the screw was from about 80.5 revolutions per minute (rpm) to about 81.5 rpm, with the temperature at the die of from about 342° F to about 346° F. The pressure in the barrel was from about 2000 psi to about 2069 psi, with the pressure at the die at from about 2079 psi to about 2196 psi. The temperature of the polymer melt at extrusion was about 297° F.
  • The tubular film was expanded by compressed air which entered the system through an inlet into the interior of said tubular film. The compressed air was utilized to expand the diameter of the tubular film to a diameter of about 3 inches. An air ring was utilized to direct the air about the exterior of extruded tubular film so as to provide quick and effective cooling. After a short distance, during which the film was allowed to cool and harden, it was wound up on a take-up roll which flattened the material, and then run through a nip roller, to produce films of varying thicknesses. The thicknesses of the films produced were about 0.003 inches, 0.004 inches, 0.006 inches, and 0.008 inches. The films thus produced had a multi-directional orientation.
  • EXAMPLE 4
  • Buttress coatings were made and applied utilizing a manual dip coating process. Briefly, from about 1% to about 6% (w/v) of paclitaxel was solubilized in a polymer solution of from about 1% to about 6% (w/v) of a glycolide/caprolactone polymer (about 10 % glycolide by weight and about 90% caprolactone by weight) using methylene chloride as a solvent.
  • After formation of this coating solution, about 10 to about 15 mL of the coating solution was dispensed into sterile 20 mL scintillation vials. Buttress discs (about 6mm in diameter) were punched from a production grade buttress made of a copolymer including about 60% by weight glycolide, about 14% by weight dioxanone, and about 26% by weight trimethylene carbonate, cleaned using an alcohol solvent wash mixture, and dried.
  • The discs were coated by direct immersion in the coating solution for approximately 30 to 60 seconds. The discs were gently removed using micro-forceps and dried under a laminar flow hood for up to 2 hours. Subsequent drying was conducted under vacuum at ambient temperature overnight, i.e., from about 12 hours to about 20 hours.
  • The amount of drug in the buttresses was determined by extraction using acetonitrile and methylene chloride. Briefly, the buttress discs were placed into a 20 mL scintillation vial (n=3). About 20 mL of acetonitrile was added to each vial and the vials were sonicated for about 2 hours using a sonicator from Fischer Scientific. A 1mL aliquot was removed from each vial, filtered with a 0.2 µm polytetrafluoroethylene (PTFE) membrane, and placed in a 2 mL HPLC vial. The samples were then injected through a high performance liquid chromatography (HPLC) column.
  • To determine if any paclitaxel remained in the polymer matrix of the buttress discs after extraction, the 3 discs were removed from the original vial, rinsed with clean acetonitrile, and placed into a new 20 mL scintillation vial. About 5 mL of methylene chloride was added to each vial and the vials were sonicated for about 1 hour. After sonication, the methylene chloride was evaporated under a stream of nitrogen and the paclitaxel was reconstituted in about 1 mL of acetonitrile. The samples were then filtered and injected through the HPLC column.
  • Paclitaxel concentrations were then measured with a Waters 2965 series HPLC (commercially available from Waters Corporation). A 20 µL from each sample was injected into a Phenomenex ODS-2 INERTSIL (5.0µm, 150mm X 4.6, from Phenomenex) which was maintained at about 30°C. The sample runs were conducted for about 10 minutes, with a flow rate at 0.8mL/minute. The mobile phase included about 55% acetonitrile and 45% water (v/v). The paclitaxel was detected at a wavelength of about 230 nm with a photodiode array detector (Waters series 2996, commercially available from Waters Corporation).
  • A graph depicting the amount of paclitaxel in the buttresses is provided as Figure 1.
  • A calibration curve was prepared by dissolving about 20 mg of paclitaxel in about 100 mL of acetonitrile to produce a 200 µg/mL stock solution. Serial dilutions of the stock solution yielded a series of standards ranging from about 0.5 µg/mL to about 20 µg/mL. The correlation coefficient was R2= .9999. Standards were filtered with a 0.2 µm PTFE membrane filter (from VWR International) prior to injection. The paclitaxel had an observed retention time of about 6.9 ± 0.2 minutes.
  • The calibration curves are provided as Figures 2A and 2B (Figure 2B is a close up of some of the peaks from Figure 2A).
  • A release medium, including phosphate buffered saline (PBS) with about 0.1% of a polyethoxylated fatty acid ester of sorbitan (also referred to as polysorbates, commercially available as TWEEN™ 80) (w/v) and about 0.5% sodium dodecylsulfate (SDS) (w/v) was prepared as follows. About 100 mL of 10X PBS concentrate was added to a 1 liter volumetric flask. The flask was filled to the line with Milli-Q water and stirred for about 15 minutes. To the solution, about 1 mL of TWEEN™ 80was added and stirred with a magnetic stir bar until the TWEEN™ 80was completely dissolved. Approximately 5 grams of sodium dodecylsulfate was then added and the solution was stirred for about 45 minutes. The pH of the solution was tested and found to be about 7.3.
  • The saturation concentration of paclitaxel in various release media was determined using the previously mentioned high pressure liquid chromatography method. In addition to the release media including PBS with about 0.1% TWEEN™ 80 and 0.5% Sodium Dodecyl Sulfate described above, other media were similarly tested. The additional media included PBS with about 0.1% by weight PLURAFAC® surfactant (commercially available from BASF), PBS with about 0.1% by weight TWEEN™ 80, and PBS with about 0.8% by weight Dimethyl-b-Cyclodextrin. A summary of the results is provided below in Table 1. TABLE 1
    Saturation Concentration of Paclitaxel in Various Media
    Media Saturation concentration of Paclitaxel (µg/mL)
    PBS w/0.1% Plurafac 0.1 ±.01
    PBS w/0.1% TWEEN™ 80 2.2 ± 0.2
    PBS w/ 0.8% Dimethyl-b-Cyclodextrin 7.3
    PBS w/0.1% TWEEN™ 80 and 0.5%
    Sodium
    Dodecyl Sulfate
    52.8 ±6.4
  • The amount of paclitaxel released from the buttresses was determined by high performance liquid chromatography (HPLC), with the results summarized in Figure 3.
  • EXAMPLE 5
  • Paclitaxel polymer coated buttresses were produced as in described in Example 4 above and evaluated for drug content and stability following sterilization. Non-sterilized materials were tested as controls. Samples were sterilized by exposure to ethylene oxide using the following parameters: 26 in Hg, 40 - 70% steam, 90 minute dwell time, 5.0 psi gas injection, 88°F to 108 °F, gas dwell time of from about 10.5 hours to about 14 hours at a gas concentration of 300 - 525 mg/L, and an air wash (8 pulses, air wash vacuum from about 20 to about 24 in Hg). Figure 5 is a graph showing the buttress drug payload of paclitaxel over time following sterilization as determined using the HPLC method described above.
  • EXAMPLE 6
  • Tumor cell lines (colorectal, lung, neural) were chosen for use in this study due to the drastic morphological changes present in healthy, adherent cells versus cells undergoing cell death or those which are loosely adherent. Healthy, adherent tumor cells are typically elongated in morphology on adhesive substrates including the tissue culture polystyrene (TCPS) used in this study. In contrast, these tumor cells take on a small, rounded morphology on non-adhesive surfaces or when undergoing cell death.
  • Tumor cells were plated into 96-well tissue culture polystyrene (TCPS) plates at a concentration of about 30,000 cells per mL in a volume of about 100 µL resulting in an initial tumor burden of about 3,000 cells. Cell culture media included Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, Manassas, VA) with about 4 mM L-glutamine (added by manufacturer) and about 10% fetal bovine serum (FBS) (ATCC, Manassas, VA). Buttresses were immersed into the cultures within 1 hour of plating (1 staple per culture). Tumor cell cultures were incubated at 37°C and 5% CO2 for 1, 3, and 7 days. Testing at particular timepoints was conducted as discussed below.
  • Tumor cell viability, cytotoxicity, and proliferation was examined at days 1, 3, and 7 by quantitatively measuring the viable tumor cell population using the MTT assay according to the manufacturer's instructions (Protocol #PR-012a). Briefly, the MTT assay measures cell density by determining the ability of the cells to reduce MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide, from Sigma) into formazan. MTT is added to the cells at a final concentration of about 0.5 mg/ml, and then incubated with the cells for about 4 hours.
  • The absorbance of the converted dye was measured using a microplate reader spectrophotometer at a wavelength of from about 556 nm to about 600 nm with background subtraction at more than about 650 nm. In the MTT assay, the measured absorbance correlated with the number of viable cells. The results of the MTT assay showed that unadulterated drug was released at therapeutic levels and concentrations capable of inhibiting cell proliferation/viability. The assay also showed no interaction between the drug and the coating material and that the drug was stable in the polymeric coating.
  • It will be understood that various modifications may be made to the embodiments disclosed herein. Therefore, the above description should not be construed as limiting, but merely as an exemplification of preferred embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the present disclosure. Such modifications and variations are intended to come within the scope of the following claims.

Claims (18)

  1. A method comprising:
    obtaining a polymeric material selected from the group consisting of glycolic acid, lactic acid, glycolide, lactide, dioxanone, trimethylene carbonate, caprolactone, and combinations thereof;
    forming the polymeric material into an article that does not possess orientation in a single direction;
    contacting the polymeric material with at least one agent selected from the group consisting of paclitaxel, DHA-paclitaxel, doxetaxel, abraxane, 5-fluorouracil, mitoxantrone, daunorubicin, doxorubicin, cisplatin, carboplatin, methotrexate, bevacizumab, antibody and prodrug conjugates of these, HER-2/neu peptides, proteins, and related vaccines, iodine 125, palladium 103, iridium 192, cesium 131, gold 198, yttrium 90, phosphorus 32, and combinations thereof; and
    recovering the article.
  2. The method of claim 1, wherein the polymeric material comprises a copolymer including glycolide in amounts from about 60% to about 75% by weight of the copolymer and trimethylene carbonate in amounts from about 25% to about 40% by weight of the copolymer.
  3. The method of claim 1, wherein the polymeric material comprises a copolymer including glycolide in amounts from about 55% to about 65% by weight of the copolymer, dioxanone in amounts from about 10% to about 18 % by weight of the copolymer, and trimethylene carbonate in amounts from about 17% to about 35% by weight of the copolymer.
  4. The method of claim 1, wherein the polymeric material comprises a copolymer including caprolactone in amounts from about 14% to about 20% by weight of the copolymer, lactide in amounts from about 4% to about 10% by weight of the copolymer, trimethylene carbonate in amounts from about 4% to about 10% by weight of the copolymer, and glycolide in amounts from about 60% to about 78% by weight of the copolymer.
  5. The method of any preceding claim, wherein forming the polymeric material into an article comprises forming an article selected from the group consisting of ribbons, tapes, sheets, and films.
  6. The method of any preceding claim, wherein forming the polymeric material into an article that does not possess orientation in a single direction results in an article possessing no orientation.
  7. The method of any of claims 1 to 5, wherein forming the polymeric material into an article that does not possess orientation in a single direction results in an article possessing multi-directional orientation.
  8. The method of any preceding claim, wherein forming the polymeric material into an article that does not possess orientation in a single direction occurs by a process selected from the group consisting of compression rollers, contoured rollers, heat pressing, blown film methods, and combinations thereof.
  9. The method of any preceding claim, wherein forming the polymeric material into an article that does not possess orientation in a single direction occurs by subjecting the polymeric material to a temperature of from about 95°C to about 230°C and a pressure of from about 1 psi to about 2500 psi, for a period of time from about 5 seconds to about 10 minutes.
  10. The method of any of claims 1 to 8, wherein forming the polymeric material into an article that does not possess orientation in a single direction occurs by introducing the polymeric material into a barrel heated to a temperature of from about 290° F to about 355° F, extruding the polymeric material through a die having a diameter of from about 1 inch to about 1.5 inches to produce a tubular film, expanding the tubular film to a diameter of from about 2 inches to about 4 inches, and flattening the tubular film to produce a film having a thickness from about 0.001 inches to about 0.014 inches.
  11. The method of any preceding claim, further comprising forming a texture on at least one surface of the article.
  12. The method of any preceding claim, wherein the article possesses a thickness of from about 0.0005 inches to about 0.014 inches or
    the method of any preceding claim, wherein the article possesses a thickness of from about 0.002 inches to about 0.005 inches.
  13. The method of any preceding claim, wherein the agent is blended with the polymeric material.
  14. The method of any preceding claim, wherein the agent comprises a coating on at least a portion of the polymeric material.
  15. A surgical stapler buttress comprising the article produced by the method of any preceding claim.
  16. A reinforcement means for a suture line comprising the article produced by the method of any of claims 1 to 14.
  17. A surgical stapling apparatus comprising:
    a staple cartridge containing at least one staple;
    an anvil having a staple forming surface; and
    a buttress positioned adjacent the anvil or the cartridge, the buttress comprising an article produced by the method of any of claims 1 to 14..
  18. The use of an article produced by a method according to any of claims 1 to 14 in sealing a wound comprising:
    enclosing tissue between a cartridge and an anvil of a surgical stapling apparatus, one of the cartridge or anvil having a buttress positioned adjacent thereto, wherein the buttress comprises an article produced by the method of any of claims 1 to 14; and
    ejecting staples from said cartridge to secure the buttress to the tissue.
EP10250641A 2009-03-31 2010-03-30 Wound closure material Withdrawn EP2243499A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/415,374 US20100076489A1 (en) 2007-03-06 2009-03-31 Wound closure material

Publications (2)

Publication Number Publication Date
EP2243499A2 true EP2243499A2 (en) 2010-10-27
EP2243499A3 EP2243499A3 (en) 2012-11-14

Family

ID=42357844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10250641A Withdrawn EP2243499A3 (en) 2009-03-31 2010-03-30 Wound closure material

Country Status (6)

Country Link
US (1) US20100076489A1 (en)
EP (1) EP2243499A3 (en)
JP (1) JP2010240411A (en)
CN (1) CN101934098A (en)
AU (1) AU2010201145A1 (en)
CA (1) CA2698161A1 (en)

Families Citing this family (468)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084897A1 (en) 2003-05-20 2007-04-19 Shelton Frederick E Iv Articulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism
US9060770B2 (en) 2003-05-20 2015-06-23 Ethicon Endo-Surgery, Inc. Robotically-driven surgical instrument with E-beam driver
US11890012B2 (en) 2004-07-28 2024-02-06 Cilag Gmbh International Staple cartridge comprising cartridge body and attached support
US8215531B2 (en) 2004-07-28 2012-07-10 Ethicon Endo-Surgery, Inc. Surgical stapling instrument having a medical substance dispenser
US11484312B2 (en) 2005-08-31 2022-11-01 Cilag Gmbh International Staple cartridge comprising a staple driver arrangement
US20070194082A1 (en) 2005-08-31 2007-08-23 Morgan Jerome R Surgical stapling device with anvil having staple forming pockets of varying depths
US9237891B2 (en) 2005-08-31 2016-01-19 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical stapling devices that produce formed staples having different lengths
US10159482B2 (en) 2005-08-31 2018-12-25 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and different staple heights
US11246590B2 (en) 2005-08-31 2022-02-15 Cilag Gmbh International Staple cartridge including staple drivers having different unfired heights
US7669746B2 (en) 2005-08-31 2010-03-02 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US7934630B2 (en) 2005-08-31 2011-05-03 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US20070106317A1 (en) 2005-11-09 2007-05-10 Shelton Frederick E Iv Hydraulically and electrically actuated articulation joints for surgical instruments
US20120292367A1 (en) 2006-01-31 2012-11-22 Ethicon Endo-Surgery, Inc. Robotically-controlled end effector
US9861359B2 (en) 2006-01-31 2018-01-09 Ethicon Llc Powered surgical instruments with firing system lockout arrangements
US7753904B2 (en) 2006-01-31 2010-07-13 Ethicon Endo-Surgery, Inc. Endoscopic surgical instrument with a handle that can articulate with respect to the shaft
US8186555B2 (en) 2006-01-31 2012-05-29 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting and fastening instrument with mechanical closure system
US20110024477A1 (en) 2009-02-06 2011-02-03 Hall Steven G Driven Surgical Stapler Improvements
US20110006101A1 (en) 2009-02-06 2011-01-13 EthiconEndo-Surgery, Inc. Motor driven surgical fastener device with cutting member lockout arrangements
US11224427B2 (en) 2006-01-31 2022-01-18 Cilag Gmbh International Surgical stapling system including a console and retraction assembly
US11278279B2 (en) 2006-01-31 2022-03-22 Cilag Gmbh International Surgical instrument assembly
US7845537B2 (en) 2006-01-31 2010-12-07 Ethicon Endo-Surgery, Inc. Surgical instrument having recording capabilities
US8708213B2 (en) 2006-01-31 2014-04-29 Ethicon Endo-Surgery, Inc. Surgical instrument having a feedback system
US8820603B2 (en) 2006-01-31 2014-09-02 Ethicon Endo-Surgery, Inc. Accessing data stored in a memory of a surgical instrument
US20110290856A1 (en) 2006-01-31 2011-12-01 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical instrument with force-feedback capabilities
US11793518B2 (en) 2006-01-31 2023-10-24 Cilag Gmbh International Powered surgical instruments with firing system lockout arrangements
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
US20070225562A1 (en) 2006-03-23 2007-09-27 Ethicon Endo-Surgery, Inc. Articulating endoscopic accessory channel
US8322455B2 (en) 2006-06-27 2012-12-04 Ethicon Endo-Surgery, Inc. Manually driven surgical cutting and fastening instrument
US10568652B2 (en) 2006-09-29 2020-02-25 Ethicon Llc Surgical staples having attached drivers of different heights and stapling instruments for deploying the same
US10130359B2 (en) 2006-09-29 2018-11-20 Ethicon Llc Method for forming a staple
US7506791B2 (en) 2006-09-29 2009-03-24 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with mechanical mechanism for limiting maximum tissue compression
US8652120B2 (en) 2007-01-10 2014-02-18 Ethicon Endo-Surgery, Inc. Surgical instrument with wireless communication between control unit and sensor transponders
US8684253B2 (en) 2007-01-10 2014-04-01 Ethicon Endo-Surgery, Inc. Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor
US11291441B2 (en) 2007-01-10 2022-04-05 Cilag Gmbh International Surgical instrument with wireless communication between control unit and remote sensor
US7434717B2 (en) 2007-01-11 2008-10-14 Ethicon Endo-Surgery, Inc. Apparatus for closing a curved anvil of a surgical stapling device
US11039836B2 (en) 2007-01-11 2021-06-22 Cilag Gmbh International Staple cartridge for use with a surgical stapling instrument
US20090001130A1 (en) 2007-03-15 2009-01-01 Hess Christopher J Surgical procedure using a cutting and stapling instrument having releasable staple-forming pockets
US8893946B2 (en) 2007-03-28 2014-11-25 Ethicon Endo-Surgery, Inc. Laparoscopic tissue thickness and clamp load measuring devices
EP2160193A4 (en) * 2007-05-14 2010-12-01 Tyco Healthcare Furanone copolymers
US11672531B2 (en) 2007-06-04 2023-06-13 Cilag Gmbh International Rotary drive systems for surgical instruments
US8931682B2 (en) 2007-06-04 2015-01-13 Ethicon Endo-Surgery, Inc. Robotically-controlled shaft based rotary drive systems for surgical instruments
US7753245B2 (en) 2007-06-22 2010-07-13 Ethicon Endo-Surgery, Inc. Surgical stapling instruments
US8408439B2 (en) 2007-06-22 2013-04-02 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with an articulatable end effector
US11849941B2 (en) 2007-06-29 2023-12-26 Cilag Gmbh International Staple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis
JP5426558B2 (en) * 2007-10-08 2014-02-26 ゴア エンタープライズ ホールディングス,インコーポレイティド Apparatus for supplying surgical stapling line reinforcement
US8561870B2 (en) 2008-02-13 2013-10-22 Ethicon Endo-Surgery, Inc. Surgical stapling instrument
US8657174B2 (en) 2008-02-14 2014-02-25 Ethicon Endo-Surgery, Inc. Motorized surgical cutting and fastening instrument having handle based power source
US7819298B2 (en) 2008-02-14 2010-10-26 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with control features operable with one hand
US8636736B2 (en) 2008-02-14 2014-01-28 Ethicon Endo-Surgery, Inc. Motorized surgical cutting and fastening instrument
RU2493788C2 (en) 2008-02-14 2013-09-27 Этикон Эндо-Серджери, Инк. Surgical cutting and fixing instrument, which has radio-frequency electrodes
US7866527B2 (en) 2008-02-14 2011-01-11 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with interlockable firing system
US9179912B2 (en) 2008-02-14 2015-11-10 Ethicon Endo-Surgery, Inc. Robotically-controlled motorized surgical cutting and fastening instrument
US8573465B2 (en) 2008-02-14 2013-11-05 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical end effector system with rotary actuated closure systems
US8758391B2 (en) 2008-02-14 2014-06-24 Ethicon Endo-Surgery, Inc. Interchangeable tools for surgical instruments
US11272927B2 (en) 2008-02-15 2022-03-15 Cilag Gmbh International Layer arrangements for surgical staple cartridges
US9585657B2 (en) 2008-02-15 2017-03-07 Ethicon Endo-Surgery, Llc Actuator for releasing a layer of material from a surgical end effector
US7954686B2 (en) 2008-09-19 2011-06-07 Ethicon Endo-Surgery, Inc. Surgical stapler with apparatus for adjusting staple height
US9005230B2 (en) 2008-09-23 2015-04-14 Ethicon Endo-Surgery, Inc. Motorized surgical instrument
US11648005B2 (en) 2008-09-23 2023-05-16 Cilag Gmbh International Robotically-controlled motorized surgical instrument with an end effector
US9386983B2 (en) 2008-09-23 2016-07-12 Ethicon Endo-Surgery, Llc Robotically-controlled motorized surgical instrument
US8210411B2 (en) 2008-09-23 2012-07-03 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument
US8608045B2 (en) 2008-10-10 2013-12-17 Ethicon Endo-Sugery, Inc. Powered surgical cutting and stapling apparatus with manually retractable firing system
US8517239B2 (en) 2009-02-05 2013-08-27 Ethicon Endo-Surgery, Inc. Surgical stapling instrument comprising a magnetic element driver
US8444036B2 (en) 2009-02-06 2013-05-21 Ethicon Endo-Surgery, Inc. Motor driven surgical fastener device with mechanisms for adjusting a tissue gap within the end effector
RU2525225C2 (en) 2009-02-06 2014-08-10 Этикон Эндо-Серджери, Инк. Improvement of drive surgical suturing instrument
US9463260B2 (en) * 2009-06-29 2016-10-11 Covidien Lp Self-sealing compositions
US8851354B2 (en) 2009-12-24 2014-10-07 Ethicon Endo-Surgery, Inc. Surgical cutting instrument that analyzes tissue thickness
US8220688B2 (en) 2009-12-24 2012-07-17 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument with electric actuator directional control assembly
US8608046B2 (en) 2010-01-07 2013-12-17 Ethicon Endo-Surgery, Inc. Test device for a surgical tool
US8783543B2 (en) 2010-07-30 2014-07-22 Ethicon Endo-Surgery, Inc. Tissue acquisition arrangements and methods for surgical stapling devices
US9289212B2 (en) 2010-09-17 2016-03-22 Ethicon Endo-Surgery, Inc. Surgical instruments and batteries for surgical instruments
US8632525B2 (en) 2010-09-17 2014-01-21 Ethicon Endo-Surgery, Inc. Power control arrangements for surgical instruments and batteries
US20120080498A1 (en) 2010-09-30 2012-04-05 Ethicon Endo-Surgery, Inc. Curved end effector for a stapling instrument
US9277919B2 (en) 2010-09-30 2016-03-08 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising fibers to produce a resilient load
US9332974B2 (en) * 2010-09-30 2016-05-10 Ethicon Endo-Surgery, Llc Layered tissue thickness compensator
US9629814B2 (en) 2010-09-30 2017-04-25 Ethicon Endo-Surgery, Llc Tissue thickness compensator configured to redistribute compressive forces
US9307989B2 (en) 2012-03-28 2016-04-12 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorportating a hydrophobic agent
US9314246B2 (en) 2010-09-30 2016-04-19 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorporating an anti-inflammatory agent
US9839420B2 (en) 2010-09-30 2017-12-12 Ethicon Llc Tissue thickness compensator comprising at least one medicament
US9386988B2 (en) 2010-09-30 2016-07-12 Ethicon End-Surgery, LLC Retainer assembly including a tissue thickness compensator
US9220501B2 (en) 2010-09-30 2015-12-29 Ethicon Endo-Surgery, Inc. Tissue thickness compensators
US10945731B2 (en) 2010-09-30 2021-03-16 Ethicon Llc Tissue thickness compensator comprising controlled release and expansion
US9414838B2 (en) 2012-03-28 2016-08-16 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprised of a plurality of materials
US9700317B2 (en) 2010-09-30 2017-07-11 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a releasable tissue thickness compensator
US8857694B2 (en) 2010-09-30 2014-10-14 Ethicon Endo-Surgery, Inc. Staple cartridge loading assembly
US11812965B2 (en) 2010-09-30 2023-11-14 Cilag Gmbh International Layer of material for a surgical end effector
US9301753B2 (en) * 2010-09-30 2016-04-05 Ethicon Endo-Surgery, Llc Expandable tissue thickness compensator
US11849952B2 (en) 2010-09-30 2023-12-26 Cilag Gmbh International Staple cartridge comprising staples positioned within a compressible portion thereof
US9517063B2 (en) 2012-03-28 2016-12-13 Ethicon Endo-Surgery, Llc Movable member for use with a tissue thickness compensator
US11298125B2 (en) 2010-09-30 2022-04-12 Cilag Gmbh International Tissue stapler having a thickness compensator
US9364233B2 (en) 2010-09-30 2016-06-14 Ethicon Endo-Surgery, Llc Tissue thickness compensators for circular surgical staplers
RU2013119928A (en) 2010-09-30 2014-11-10 Этикон Эндо-Серджери, Инк. A STAPLING SYSTEM CONTAINING A RETAINING MATRIX AND A LEVELING MATRIX
US8695866B2 (en) 2010-10-01 2014-04-15 Ethicon Endo-Surgery, Inc. Surgical instrument having a power control circuit
AU2012250197B2 (en) 2011-04-29 2017-08-10 Ethicon Endo-Surgery, Inc. Staple cartridge comprising staples positioned within a compressible portion thereof
US11207064B2 (en) 2011-05-27 2021-12-28 Cilag Gmbh International Automated end effector component reloading system for use with a robotic system
US9072535B2 (en) 2011-05-27 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling instruments with rotatable staple deployment arrangements
US9050084B2 (en) 2011-09-23 2015-06-09 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck arrangement
US9044230B2 (en) 2012-02-13 2015-06-02 Ethicon Endo-Surgery, Inc. Surgical cutting and fastening instrument with apparatus for determining cartridge and firing motion status
MX358135B (en) * 2012-03-28 2018-08-06 Ethicon Endo Surgery Inc Tissue thickness compensator comprising a plurality of layers.
CN104379068B (en) 2012-03-28 2017-09-22 伊西康内外科公司 Holding device assembly including tissue thickness compensation part
MX355789B (en) * 2012-03-28 2018-04-27 Ethicon Endo Surgery Inc Tissue thickness compensator comprising tissue ingrowth features.
JP6266590B2 (en) * 2012-03-28 2018-01-24 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Tissue thickness compensator with channel
MX350846B (en) 2012-03-28 2017-09-22 Ethicon Endo Surgery Inc Tissue thickness compensator comprising capsules defining a low pressure environment.
RU2648844C2 (en) * 2012-03-28 2018-03-28 Этикон Эндо-Серджери, Инк. Tissue thickness compensator containing plurality of capsules
US9198662B2 (en) * 2012-03-28 2015-12-01 Ethicon Endo-Surgery, Inc. Tissue thickness compensator having improved visibility
US9101358B2 (en) 2012-06-15 2015-08-11 Ethicon Endo-Surgery, Inc. Articulatable surgical instrument comprising a firing drive
US20140001231A1 (en) 2012-06-28 2014-01-02 Ethicon Endo-Surgery, Inc. Firing system lockout arrangements for surgical instruments
US20140005678A1 (en) 2012-06-28 2014-01-02 Ethicon Endo-Surgery, Inc. Rotary drive arrangements for surgical instruments
BR112014032776B1 (en) 2012-06-28 2021-09-08 Ethicon Endo-Surgery, Inc SURGICAL INSTRUMENT SYSTEM AND SURGICAL KIT FOR USE WITH A SURGICAL INSTRUMENT SYSTEM
US11202631B2 (en) 2012-06-28 2021-12-21 Cilag Gmbh International Stapling assembly comprising a firing lockout
US9119657B2 (en) 2012-06-28 2015-09-01 Ethicon Endo-Surgery, Inc. Rotary actuatable closure arrangement for surgical end effector
US9289256B2 (en) 2012-06-28 2016-03-22 Ethicon Endo-Surgery, Llc Surgical end effectors having angled tissue-contacting surfaces
JP6290201B2 (en) 2012-06-28 2018-03-07 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Lockout for empty clip cartridge
US9028494B2 (en) 2012-06-28 2015-05-12 Ethicon Endo-Surgery, Inc. Interchangeable end effector coupling arrangement
US9561038B2 (en) 2012-06-28 2017-02-07 Ethicon Endo-Surgery, Llc Interchangeable clip applier
US9072536B2 (en) 2012-06-28 2015-07-07 Ethicon Endo-Surgery, Inc. Differential locking arrangements for rotary powered surgical instruments
US20140005718A1 (en) 2012-06-28 2014-01-02 Ethicon Endo-Surgery, Inc. Multi-functional powered surgical device with external dissection features
US9125662B2 (en) 2012-06-28 2015-09-08 Ethicon Endo-Surgery, Inc. Multi-axis articulating and rotating surgical tools
US9101385B2 (en) 2012-06-28 2015-08-11 Ethicon Endo-Surgery, Inc. Electrode connections for rotary driven surgical tools
US9649111B2 (en) 2012-06-28 2017-05-16 Ethicon Endo-Surgery, Llc Replaceable clip cartridge for a clip applier
US9386984B2 (en) 2013-02-08 2016-07-12 Ethicon Endo-Surgery, Llc Staple cartridge comprising a releasable cover
US9307986B2 (en) 2013-03-01 2016-04-12 Ethicon Endo-Surgery, Llc Surgical instrument soft stop
JP6382235B2 (en) 2013-03-01 2018-08-29 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Articulatable surgical instrument with a conductive path for signal communication
MX364729B (en) 2013-03-01 2019-05-06 Ethicon Endo Surgery Inc Surgical instrument with a soft stop.
US9345481B2 (en) 2013-03-13 2016-05-24 Ethicon Endo-Surgery, Llc Staple cartridge tissue thickness sensor system
US9629629B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgey, LLC Control systems for surgical instruments
US9808244B2 (en) 2013-03-14 2017-11-07 Ethicon Llc Sensor arrangements for absolute positioning system for surgical instruments
US9795384B2 (en) 2013-03-27 2017-10-24 Ethicon Llc Fastener cartridge comprising a tissue thickness compensator and a gap setting element
US9332984B2 (en) 2013-03-27 2016-05-10 Ethicon Endo-Surgery, Llc Fastener cartridge assemblies
US9572577B2 (en) 2013-03-27 2017-02-21 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a tissue thickness compensator including openings therein
BR112015026109B1 (en) 2013-04-16 2022-02-22 Ethicon Endo-Surgery, Inc surgical instrument
US9826976B2 (en) 2013-04-16 2017-11-28 Ethicon Llc Motor driven surgical instruments with lockable dual drive shafts
US9574644B2 (en) 2013-05-30 2017-02-21 Ethicon Endo-Surgery, Llc Power module for use with a surgical instrument
MX369362B (en) 2013-08-23 2019-11-06 Ethicon Endo Surgery Llc Firing member retraction devices for powered surgical instruments.
US9808249B2 (en) 2013-08-23 2017-11-07 Ethicon Llc Attachment portions for surgical instrument assemblies
US9549735B2 (en) 2013-12-23 2017-01-24 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a firing member including fastener transfer surfaces
US9839428B2 (en) 2013-12-23 2017-12-12 Ethicon Llc Surgical cutting and stapling instruments with independent jaw control features
US20150173756A1 (en) 2013-12-23 2015-06-25 Ethicon Endo-Surgery, Inc. Surgical cutting and stapling methods
US9724092B2 (en) 2013-12-23 2017-08-08 Ethicon Llc Modular surgical instruments
US9681870B2 (en) 2013-12-23 2017-06-20 Ethicon Llc Articulatable surgical instruments with separate and distinct closing and firing systems
US9642620B2 (en) 2013-12-23 2017-05-09 Ethicon Endo-Surgery, Llc Surgical cutting and stapling instruments with articulatable end effectors
US9962161B2 (en) 2014-02-12 2018-05-08 Ethicon Llc Deliverable surgical instrument
US20140166726A1 (en) 2014-02-24 2014-06-19 Ethicon Endo-Surgery, Inc. Staple cartridge including a barbed staple
CA2940512C (en) * 2014-02-24 2023-03-14 Ethicon Endo-Surgery, Llc Implantable layers and methods for modifying the shape of the implantable layers for use with a surgical fastening instrument
CN106232029B (en) 2014-02-24 2019-04-12 伊西康内外科有限责任公司 Fastening system including firing member locking piece
JP6542267B2 (en) * 2014-02-24 2019-07-10 エシコン エルエルシーEthicon LLC Embedded layer including pressed area
US20150272557A1 (en) 2014-03-26 2015-10-01 Ethicon Endo-Surgery, Inc. Modular surgical instrument system
US9826977B2 (en) 2014-03-26 2017-11-28 Ethicon Llc Sterilization verification circuit
US9913642B2 (en) 2014-03-26 2018-03-13 Ethicon Llc Surgical instrument comprising a sensor system
BR112016021943B1 (en) 2014-03-26 2022-06-14 Ethicon Endo-Surgery, Llc SURGICAL INSTRUMENT FOR USE BY AN OPERATOR IN A SURGICAL PROCEDURE
US10201364B2 (en) 2014-03-26 2019-02-12 Ethicon Llc Surgical instrument comprising a rotatable shaft
US10542988B2 (en) 2014-04-16 2020-01-28 Ethicon Llc End effector comprising an anvil including projections extending therefrom
US9801628B2 (en) 2014-09-26 2017-10-31 Ethicon Llc Surgical staple and driver arrangements for staple cartridges
CN106456176B (en) 2014-04-16 2019-06-28 伊西康内外科有限责任公司 Fastener cartridge including the extension with various configuration
BR112016023807B1 (en) 2014-04-16 2022-07-12 Ethicon Endo-Surgery, Llc CARTRIDGE SET OF FASTENERS FOR USE WITH A SURGICAL INSTRUMENT
US20150297223A1 (en) 2014-04-16 2015-10-22 Ethicon Endo-Surgery, Inc. Fastener cartridges including extensions having different configurations
JP6612256B2 (en) 2014-04-16 2019-11-27 エシコン エルエルシー Fastener cartridge with non-uniform fastener
US10045781B2 (en) 2014-06-13 2018-08-14 Ethicon Llc Closure lockout systems for surgical instruments
US9724094B2 (en) 2014-09-05 2017-08-08 Ethicon Llc Adjunct with integrated sensors to quantify tissue compression
US11311294B2 (en) 2014-09-05 2022-04-26 Cilag Gmbh International Powered medical device including measurement of closure state of jaws
BR112017004361B1 (en) 2014-09-05 2023-04-11 Ethicon Llc ELECTRONIC SYSTEM FOR A SURGICAL INSTRUMENT
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
US11523821B2 (en) 2014-09-26 2022-12-13 Cilag Gmbh International Method for creating a flexible staple line
CN107427300B (en) 2014-09-26 2020-12-04 伊西康有限责任公司 Surgical suture buttress and buttress material
US10076325B2 (en) 2014-10-13 2018-09-18 Ethicon Llc Surgical stapling apparatus comprising a tissue stop
US9924944B2 (en) 2014-10-16 2018-03-27 Ethicon Llc Staple cartridge comprising an adjunct material
US11141153B2 (en) 2014-10-29 2021-10-12 Cilag Gmbh International Staple cartridges comprising driver arrangements
US10517594B2 (en) 2014-10-29 2019-12-31 Ethicon Llc Cartridge assemblies for surgical staplers
US9844376B2 (en) 2014-11-06 2017-12-19 Ethicon Llc Staple cartridge comprising a releasable adjunct material
US10736636B2 (en) 2014-12-10 2020-08-11 Ethicon Llc Articulatable surgical instrument system
US9844374B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US10085748B2 (en) 2014-12-18 2018-10-02 Ethicon Llc Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors
US10245027B2 (en) 2014-12-18 2019-04-02 Ethicon Llc Surgical instrument with an anvil that is selectively movable about a discrete non-movable axis relative to a staple cartridge
US10188385B2 (en) 2014-12-18 2019-01-29 Ethicon Llc Surgical instrument system comprising lockable systems
US9844375B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Drive arrangements for articulatable surgical instruments
US9987000B2 (en) 2014-12-18 2018-06-05 Ethicon Llc Surgical instrument assembly comprising a flexible articulation system
US10117649B2 (en) 2014-12-18 2018-11-06 Ethicon Llc Surgical instrument assembly comprising a lockable articulation system
BR112017012996B1 (en) 2014-12-18 2022-11-08 Ethicon Llc SURGICAL INSTRUMENT WITH AN ANvil WHICH IS SELECTIVELY MOVABLE ABOUT AN IMMOVABLE GEOMETRIC AXIS DIFFERENT FROM A STAPLE CARTRIDGE
US10245028B2 (en) 2015-02-27 2019-04-02 Ethicon Llc Power adapter for a surgical instrument
US11154301B2 (en) 2015-02-27 2021-10-26 Cilag Gmbh International Modular stapling assembly
US10180463B2 (en) 2015-02-27 2019-01-15 Ethicon Llc Surgical apparatus configured to assess whether a performance parameter of the surgical apparatus is within an acceptable performance band
US9993258B2 (en) 2015-02-27 2018-06-12 Ethicon Llc Adaptable surgical instrument handle
US9895148B2 (en) 2015-03-06 2018-02-20 Ethicon Endo-Surgery, Llc Monitoring speed control and precision incrementing of motor for powered surgical instruments
US10045776B2 (en) 2015-03-06 2018-08-14 Ethicon Llc Control techniques and sub-processor contained within modular shaft with select control processing from handle
US9901342B2 (en) 2015-03-06 2018-02-27 Ethicon Endo-Surgery, Llc Signal and power communication system positioned on a rotatable shaft
US9924961B2 (en) 2015-03-06 2018-03-27 Ethicon Endo-Surgery, Llc Interactive feedback system for powered surgical instruments
US10052044B2 (en) 2015-03-06 2018-08-21 Ethicon Llc Time dependent evaluation of sensor data to determine stability, creep, and viscoelastic elements of measures
JP2020121162A (en) 2015-03-06 2020-08-13 エシコン エルエルシーEthicon LLC Time dependent evaluation of sensor data to determine stability element, creep element and viscoelastic element of measurement
US10245033B2 (en) 2015-03-06 2019-04-02 Ethicon Llc Surgical instrument comprising a lockable battery housing
US10687806B2 (en) 2015-03-06 2020-06-23 Ethicon Llc Adaptive tissue compression techniques to adjust closure rates for multiple tissue types
US9808246B2 (en) 2015-03-06 2017-11-07 Ethicon Endo-Surgery, Llc Method of operating a powered surgical instrument
US9993248B2 (en) 2015-03-06 2018-06-12 Ethicon Endo-Surgery, Llc Smart sensors with local signal processing
US10617412B2 (en) 2015-03-06 2020-04-14 Ethicon Llc System for detecting the mis-insertion of a staple cartridge into a surgical stapler
US10213201B2 (en) 2015-03-31 2019-02-26 Ethicon Llc Stapling end effector configured to compensate for an uneven gap between a first jaw and a second jaw
US10086109B2 (en) * 2015-06-02 2018-10-02 Ethicon, Inc. Absorbable medical devices based on novel films and foams made from semi-crystalline, segmented copolymers of lactide and epsilon-caprolactone exhibiting long term absorption characteristics
US10405863B2 (en) 2015-06-18 2019-09-10 Ethicon Llc Movable firing beam support arrangements for articulatable surgical instruments
US11058425B2 (en) 2015-08-17 2021-07-13 Ethicon Llc Implantable layers for a surgical instrument
US10028744B2 (en) 2015-08-26 2018-07-24 Ethicon Llc Staple cartridge assembly including staple guides
MX2018002388A (en) 2015-08-26 2018-08-01 Ethicon Llc Surgical staple strips for permitting varying staple properties and enabling easy cartridge loading.
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US10285692B2 (en) * 2015-08-31 2019-05-14 Ethicon Llc Adjuncts for surgical devices including agonists and antagonists
US10188390B2 (en) * 2015-08-31 2019-01-29 Ethicon Llc Adjunct material to provide heterogeneous drug elution
US10213520B2 (en) * 2015-08-31 2019-02-26 Ethicon Llc Surgical adjuncts having medicants controllably releasable therefrom
MX2022006191A (en) 2015-09-02 2022-06-16 Ethicon Llc Surgical staple configurations with camming surfaces located between portions supporting surgical staples.
US10172619B2 (en) 2015-09-02 2019-01-08 Ethicon Llc Surgical staple driver arrays
US10076326B2 (en) 2015-09-23 2018-09-18 Ethicon Llc Surgical stapler having current mirror-based motor control
US10238386B2 (en) 2015-09-23 2019-03-26 Ethicon Llc Surgical stapler having motor control based on an electrical parameter related to a motor current
US10105139B2 (en) 2015-09-23 2018-10-23 Ethicon Llc Surgical stapler having downstream current-based motor control
US10327769B2 (en) 2015-09-23 2019-06-25 Ethicon Llc Surgical stapler having motor control based on a drive system component
US10363036B2 (en) 2015-09-23 2019-07-30 Ethicon Llc Surgical stapler having force-based motor control
US10085751B2 (en) 2015-09-23 2018-10-02 Ethicon Llc Surgical stapler having temperature-based motor control
US10299878B2 (en) 2015-09-25 2019-05-28 Ethicon Llc Implantable adjunct systems for determining adjunct skew
US10524788B2 (en) 2015-09-30 2020-01-07 Ethicon Llc Compressible adjunct with attachment regions
US10285699B2 (en) 2015-09-30 2019-05-14 Ethicon Llc Compressible adjunct
US10980539B2 (en) 2015-09-30 2021-04-20 Ethicon Llc Implantable adjunct comprising bonded layers
US11890015B2 (en) 2015-09-30 2024-02-06 Cilag Gmbh International Compressible adjunct with crossing spacer fibers
US10368865B2 (en) 2015-12-30 2019-08-06 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits
US10292704B2 (en) 2015-12-30 2019-05-21 Ethicon Llc Mechanisms for compensating for battery pack failure in powered surgical instruments
US10588625B2 (en) 2016-02-09 2020-03-17 Ethicon Llc Articulatable surgical instruments with off-axis firing beam arrangements
BR112018016098B1 (en) 2016-02-09 2023-02-23 Ethicon Llc SURGICAL INSTRUMENT
US11213293B2 (en) 2016-02-09 2022-01-04 Cilag Gmbh International Articulatable surgical instruments with single articulation link arrangements
US10258331B2 (en) 2016-02-12 2019-04-16 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US11224426B2 (en) 2016-02-12 2022-01-18 Cilag Gmbh International Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10448948B2 (en) 2016-02-12 2019-10-22 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10617413B2 (en) 2016-04-01 2020-04-14 Ethicon Llc Closure system arrangements for surgical cutting and stapling devices with separate and distinct firing shafts
US11064997B2 (en) 2016-04-01 2021-07-20 Cilag Gmbh International Surgical stapling instrument
US10456137B2 (en) 2016-04-15 2019-10-29 Ethicon Llc Staple formation detection mechanisms
US10335145B2 (en) 2016-04-15 2019-07-02 Ethicon Llc Modular surgical instrument with configurable operating mode
US10405859B2 (en) 2016-04-15 2019-09-10 Ethicon Llc Surgical instrument with adjustable stop/start control during a firing motion
US10426467B2 (en) 2016-04-15 2019-10-01 Ethicon Llc Surgical instrument with detection sensors
US10492783B2 (en) 2016-04-15 2019-12-03 Ethicon, Llc Surgical instrument with improved stop/start control during a firing motion
US11179150B2 (en) 2016-04-15 2021-11-23 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10828028B2 (en) 2016-04-15 2020-11-10 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US11607239B2 (en) 2016-04-15 2023-03-21 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10357247B2 (en) 2016-04-15 2019-07-23 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US11317917B2 (en) 2016-04-18 2022-05-03 Cilag Gmbh International Surgical stapling system comprising a lockable firing assembly
US20170296173A1 (en) 2016-04-18 2017-10-19 Ethicon Endo-Surgery, Llc Method for operating a surgical instrument
US10363037B2 (en) 2016-04-18 2019-07-30 Ethicon Llc Surgical instrument system comprising a magnetic lockout
US11000278B2 (en) 2016-06-24 2021-05-11 Ethicon Llc Staple cartridge comprising wire staples and stamped staples
CN109310431B (en) 2016-06-24 2022-03-04 伊西康有限责任公司 Staple cartridge comprising wire staples and punch staples
USD826405S1 (en) 2016-06-24 2018-08-21 Ethicon Llc Surgical fastener
USD850617S1 (en) 2016-06-24 2019-06-04 Ethicon Llc Surgical fastener cartridge
USD847989S1 (en) 2016-06-24 2019-05-07 Ethicon Llc Surgical fastener cartridge
US10758229B2 (en) 2016-12-21 2020-09-01 Ethicon Llc Surgical instrument comprising improved jaw control
JP7010956B2 (en) 2016-12-21 2022-01-26 エシコン エルエルシー How to staple tissue
CN110099619B (en) 2016-12-21 2022-07-15 爱惜康有限责任公司 Lockout device for surgical end effector and replaceable tool assembly
US10568626B2 (en) 2016-12-21 2020-02-25 Ethicon Llc Surgical instruments with jaw opening features for increasing a jaw opening distance
US10945727B2 (en) 2016-12-21 2021-03-16 Ethicon Llc Staple cartridge with deformable driver retention features
US10426471B2 (en) 2016-12-21 2019-10-01 Ethicon Llc Surgical instrument with multiple failure response modes
US20180168615A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument
US10675025B2 (en) 2016-12-21 2020-06-09 Ethicon Llc Shaft assembly comprising separately actuatable and retractable systems
US20180168598A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Staple forming pocket arrangements comprising zoned forming surface grooves
US10568625B2 (en) 2016-12-21 2020-02-25 Ethicon Llc Staple cartridges and arrangements of staples and staple cavities therein
US11684367B2 (en) 2016-12-21 2023-06-27 Cilag Gmbh International Stepped assembly having and end-of-life indicator
US11134942B2 (en) 2016-12-21 2021-10-05 Cilag Gmbh International Surgical stapling instruments and staple-forming anvils
BR112019011947A2 (en) 2016-12-21 2019-10-29 Ethicon Llc surgical stapling systems
US10959727B2 (en) 2016-12-21 2021-03-30 Ethicon Llc Articulatable surgical end effector with asymmetric shaft arrangement
US10667810B2 (en) 2016-12-21 2020-06-02 Ethicon Llc Closure members with cam surface arrangements for surgical instruments with separate and distinct closure and firing systems
US10973516B2 (en) 2016-12-21 2021-04-13 Ethicon Llc Surgical end effectors and adaptable firing members therefor
US10687810B2 (en) 2016-12-21 2020-06-23 Ethicon Llc Stepped staple cartridge with tissue retention and gap setting features
US20180168625A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Surgical stapling instruments with smart staple cartridges
US11090048B2 (en) 2016-12-21 2021-08-17 Cilag Gmbh International Method for resetting a fuse of a surgical instrument shaft
US11419606B2 (en) 2016-12-21 2022-08-23 Cilag Gmbh International Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems
US10667809B2 (en) 2016-12-21 2020-06-02 Ethicon Llc Staple cartridge and staple cartridge channel comprising windows defined therein
US20180168648A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Durability features for end effectors and firing assemblies of surgical stapling instruments
US10485543B2 (en) 2016-12-21 2019-11-26 Ethicon Llc Anvil having a knife slot width
US10993715B2 (en) 2016-12-21 2021-05-04 Ethicon Llc Staple cartridge comprising staples with different clamping breadths
US10874768B2 (en) 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
US11653914B2 (en) 2017-06-20 2023-05-23 Cilag Gmbh International Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector
US11090046B2 (en) 2017-06-20 2021-08-17 Cilag Gmbh International Systems and methods for controlling displacement member motion of a surgical stapling and cutting instrument
US11382638B2 (en) 2017-06-20 2022-07-12 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance
US10646220B2 (en) 2017-06-20 2020-05-12 Ethicon Llc Systems and methods for controlling displacement member velocity for a surgical instrument
USD879809S1 (en) 2017-06-20 2020-03-31 Ethicon Llc Display panel with changeable graphical user interface
US10813639B2 (en) 2017-06-20 2020-10-27 Ethicon Llc Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on system conditions
USD890784S1 (en) 2017-06-20 2020-07-21 Ethicon Llc Display panel with changeable graphical user interface
US10368864B2 (en) 2017-06-20 2019-08-06 Ethicon Llc Systems and methods for controlling displaying motor velocity for a surgical instrument
US10624633B2 (en) 2017-06-20 2020-04-21 Ethicon Llc Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument
US10980537B2 (en) 2017-06-20 2021-04-20 Ethicon Llc Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified number of shaft rotations
US10881399B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Techniques for adaptive control of motor velocity of a surgical stapling and cutting instrument
USD879808S1 (en) 2017-06-20 2020-03-31 Ethicon Llc Display panel with graphical user interface
US10307170B2 (en) 2017-06-20 2019-06-04 Ethicon Llc Method for closed loop control of motor velocity of a surgical stapling and cutting instrument
US10881396B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Surgical instrument with variable duration trigger arrangement
US11517325B2 (en) 2017-06-20 2022-12-06 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval
US11071554B2 (en) 2017-06-20 2021-07-27 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements
US10390841B2 (en) 2017-06-20 2019-08-27 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10327767B2 (en) 2017-06-20 2019-06-25 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10779820B2 (en) 2017-06-20 2020-09-22 Ethicon Llc Systems and methods for controlling motor speed according to user input for a surgical instrument
US10888321B2 (en) 2017-06-20 2021-01-12 Ethicon Llc Systems and methods for controlling velocity of a displacement member of a surgical stapling and cutting instrument
US10856869B2 (en) 2017-06-27 2020-12-08 Ethicon Llc Surgical anvil arrangements
US10772629B2 (en) 2017-06-27 2020-09-15 Ethicon Llc Surgical anvil arrangements
US20180368844A1 (en) 2017-06-27 2018-12-27 Ethicon Llc Staple forming pocket arrangements
US11266405B2 (en) 2017-06-27 2022-03-08 Cilag Gmbh International Surgical anvil manufacturing methods
US11324503B2 (en) 2017-06-27 2022-05-10 Cilag Gmbh International Surgical firing member arrangements
US10993716B2 (en) 2017-06-27 2021-05-04 Ethicon Llc Surgical anvil arrangements
US10716614B2 (en) 2017-06-28 2020-07-21 Ethicon Llc Surgical shaft assemblies with slip ring assemblies with increased contact pressure
USD869655S1 (en) 2017-06-28 2019-12-10 Ethicon Llc Surgical fastener cartridge
US10211586B2 (en) 2017-06-28 2019-02-19 Ethicon Llc Surgical shaft assemblies with watertight housings
USD906355S1 (en) 2017-06-28 2020-12-29 Ethicon Llc Display screen or portion thereof with a graphical user interface for a surgical instrument
US11259805B2 (en) 2017-06-28 2022-03-01 Cilag Gmbh International Surgical instrument comprising firing member supports
US11389161B2 (en) 2017-06-28 2022-07-19 Cilag Gmbh International Surgical instrument comprising selectively actuatable rotatable couplers
US11564686B2 (en) 2017-06-28 2023-01-31 Cilag Gmbh International Surgical shaft assemblies with flexible interfaces
US11246592B2 (en) 2017-06-28 2022-02-15 Cilag Gmbh International Surgical instrument comprising an articulation system lockable to a frame
US10903685B2 (en) 2017-06-28 2021-01-26 Ethicon Llc Surgical shaft assemblies with slip ring assemblies forming capacitive channels
USD851762S1 (en) 2017-06-28 2019-06-18 Ethicon Llc Anvil
US11478242B2 (en) 2017-06-28 2022-10-25 Cilag Gmbh International Jaw retainer arrangement for retaining a pivotable surgical instrument jaw in pivotable retaining engagement with a second surgical instrument jaw
US10765427B2 (en) 2017-06-28 2020-09-08 Ethicon Llc Method for articulating a surgical instrument
USD854151S1 (en) 2017-06-28 2019-07-16 Ethicon Llc Surgical instrument shaft
EP4070740A1 (en) 2017-06-28 2022-10-12 Cilag GmbH International Surgical instrument comprising selectively actuatable rotatable couplers
US11007022B2 (en) 2017-06-29 2021-05-18 Ethicon Llc Closed loop velocity control techniques based on sensed tissue parameters for robotic surgical instrument
US10258418B2 (en) 2017-06-29 2019-04-16 Ethicon Llc System for controlling articulation forces
US10398434B2 (en) 2017-06-29 2019-09-03 Ethicon Llc Closed loop velocity control of closure member for robotic surgical instrument
US10932772B2 (en) 2017-06-29 2021-03-02 Ethicon Llc Methods for closed loop velocity control for robotic surgical instrument
US10898183B2 (en) 2017-06-29 2021-01-26 Ethicon Llc Robotic surgical instrument with closed loop feedback techniques for advancement of closure member during firing
US20190021730A1 (en) * 2017-07-18 2019-01-24 Covidien Lp Drug eluting medical device
US11304695B2 (en) 2017-08-03 2022-04-19 Cilag Gmbh International Surgical system shaft interconnection
US11471155B2 (en) 2017-08-03 2022-10-18 Cilag Gmbh International Surgical system bailout
US10743872B2 (en) 2017-09-29 2020-08-18 Ethicon Llc System and methods for controlling a display of a surgical instrument
USD917500S1 (en) 2017-09-29 2021-04-27 Ethicon Llc Display screen or portion thereof with graphical user interface
US11399829B2 (en) 2017-09-29 2022-08-02 Cilag Gmbh International Systems and methods of initiating a power shutdown mode for a surgical instrument
US10796471B2 (en) 2017-09-29 2020-10-06 Ethicon Llc Systems and methods of displaying a knife position for a surgical instrument
US10729501B2 (en) 2017-09-29 2020-08-04 Ethicon Llc Systems and methods for language selection of a surgical instrument
USD907647S1 (en) 2017-09-29 2021-01-12 Ethicon Llc Display screen or portion thereof with animated graphical user interface
US10765429B2 (en) 2017-09-29 2020-09-08 Ethicon Llc Systems and methods for providing alerts according to the operational state of a surgical instrument
USD907648S1 (en) 2017-09-29 2021-01-12 Ethicon Llc Display screen or portion thereof with animated graphical user interface
US11090075B2 (en) 2017-10-30 2021-08-17 Cilag Gmbh International Articulation features for surgical end effector
US11134944B2 (en) 2017-10-30 2021-10-05 Cilag Gmbh International Surgical stapler knife motion controls
US10842490B2 (en) 2017-10-31 2020-11-24 Ethicon Llc Cartridge body design with force reduction based on firing completion
US10779903B2 (en) 2017-10-31 2020-09-22 Ethicon Llc Positive shaft rotation lock activated by jaw closure
US10687813B2 (en) 2017-12-15 2020-06-23 Ethicon Llc Adapters with firing stroke sensing arrangements for use in connection with electromechanical surgical instruments
US10743875B2 (en) 2017-12-15 2020-08-18 Ethicon Llc Surgical end effectors with jaw stiffener arrangements configured to permit monitoring of firing member
US10743874B2 (en) 2017-12-15 2020-08-18 Ethicon Llc Sealed adapters for use with electromechanical surgical instruments
US10966718B2 (en) 2017-12-15 2021-04-06 Ethicon Llc Dynamic clamping assemblies with improved wear characteristics for use in connection with electromechanical surgical instruments
US11033267B2 (en) 2017-12-15 2021-06-15 Ethicon Llc Systems and methods of controlling a clamping member firing rate of a surgical instrument
US11071543B2 (en) 2017-12-15 2021-07-27 Cilag Gmbh International Surgical end effectors with clamping assemblies configured to increase jaw aperture ranges
US10779825B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Adapters with end effector position sensing and control arrangements for use in connection with electromechanical surgical instruments
US10779826B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Methods of operating surgical end effectors
US10869666B2 (en) 2017-12-15 2020-12-22 Ethicon Llc Adapters with control systems for controlling multiple motors of an electromechanical surgical instrument
US10828033B2 (en) 2017-12-15 2020-11-10 Ethicon Llc Handheld electromechanical surgical instruments with improved motor control arrangements for positioning components of an adapter coupled thereto
US11006955B2 (en) 2017-12-15 2021-05-18 Ethicon Llc End effectors with positive jaw opening features for use with adapters for electromechanical surgical instruments
US11197670B2 (en) 2017-12-15 2021-12-14 Cilag Gmbh International Surgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed
US10716565B2 (en) 2017-12-19 2020-07-21 Ethicon Llc Surgical instruments with dual articulation drivers
US10729509B2 (en) 2017-12-19 2020-08-04 Ethicon Llc Surgical instrument comprising closure and firing locking mechanism
US11045270B2 (en) 2017-12-19 2021-06-29 Cilag Gmbh International Robotic attachment comprising exterior drive actuator
US10835330B2 (en) 2017-12-19 2020-11-17 Ethicon Llc Method for determining the position of a rotatable jaw of a surgical instrument attachment assembly
USD910847S1 (en) 2017-12-19 2021-02-16 Ethicon Llc Surgical instrument assembly
US11020112B2 (en) 2017-12-19 2021-06-01 Ethicon Llc Surgical tools configured for interchangeable use with different controller interfaces
US11129680B2 (en) 2017-12-21 2021-09-28 Cilag Gmbh International Surgical instrument comprising a projector
US11076853B2 (en) 2017-12-21 2021-08-03 Cilag Gmbh International Systems and methods of displaying a knife position during transection for a surgical instrument
US11311290B2 (en) 2017-12-21 2022-04-26 Cilag Gmbh International Surgical instrument comprising an end effector dampener
US10682134B2 (en) 2017-12-21 2020-06-16 Ethicon Llc Continuous use self-propelled stapling instrument
US11039834B2 (en) 2018-08-20 2021-06-22 Cilag Gmbh International Surgical stapler anvils with staple directing protrusions and tissue stability features
US11324501B2 (en) 2018-08-20 2022-05-10 Cilag Gmbh International Surgical stapling devices with improved closure members
US10842492B2 (en) 2018-08-20 2020-11-24 Ethicon Llc Powered articulatable surgical instruments with clutching and locking arrangements for linking an articulation drive system to a firing drive system
US10912559B2 (en) 2018-08-20 2021-02-09 Ethicon Llc Reinforced deformable anvil tip for surgical stapler anvil
US10779821B2 (en) 2018-08-20 2020-09-22 Ethicon Llc Surgical stapler anvils with tissue stop features configured to avoid tissue pinch
US11253256B2 (en) 2018-08-20 2022-02-22 Cilag Gmbh International Articulatable motor powered surgical instruments with dedicated articulation motor arrangements
US11083458B2 (en) 2018-08-20 2021-08-10 Cilag Gmbh International Powered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions
US10856870B2 (en) 2018-08-20 2020-12-08 Ethicon Llc Switching arrangements for motor powered articulatable surgical instruments
US11045192B2 (en) 2018-08-20 2021-06-29 Cilag Gmbh International Fabricating techniques for surgical stapler anvils
US11207065B2 (en) 2018-08-20 2021-12-28 Cilag Gmbh International Method for fabricating surgical stapler anvils
USD914878S1 (en) 2018-08-20 2021-03-30 Ethicon Llc Surgical instrument anvil
US11291440B2 (en) 2018-08-20 2022-04-05 Cilag Gmbh International Method for operating a powered articulatable surgical instrument
US11172929B2 (en) 2019-03-25 2021-11-16 Cilag Gmbh International Articulation drive arrangements for surgical systems
US11147553B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11147551B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11696761B2 (en) 2019-03-25 2023-07-11 Cilag Gmbh International Firing drive arrangements for surgical systems
US11471157B2 (en) 2019-04-30 2022-10-18 Cilag Gmbh International Articulation control mapping for a surgical instrument
US11253254B2 (en) 2019-04-30 2022-02-22 Cilag Gmbh International Shaft rotation actuator on a surgical instrument
US11903581B2 (en) 2019-04-30 2024-02-20 Cilag Gmbh International Methods for stapling tissue using a surgical instrument
US11432816B2 (en) 2019-04-30 2022-09-06 Cilag Gmbh International Articulation pin for a surgical instrument
US11452528B2 (en) 2019-04-30 2022-09-27 Cilag Gmbh International Articulation actuators for a surgical instrument
US11648009B2 (en) 2019-04-30 2023-05-16 Cilag Gmbh International Rotatable jaw tip for a surgical instrument
US11426251B2 (en) 2019-04-30 2022-08-30 Cilag Gmbh International Articulation directional lights on a surgical instrument
US11596403B2 (en) 2019-05-08 2023-03-07 Covidien Lp Surgical stapling device
US11478245B2 (en) 2019-05-08 2022-10-25 Covidien Lp Surgical stapling device
US11464601B2 (en) 2019-06-28 2022-10-11 Cilag Gmbh International Surgical instrument comprising an RFID system for tracking a movable component
US11771419B2 (en) 2019-06-28 2023-10-03 Cilag Gmbh International Packaging for a replaceable component of a surgical stapling system
US11523822B2 (en) 2019-06-28 2022-12-13 Cilag Gmbh International Battery pack including a circuit interrupter
US11426167B2 (en) 2019-06-28 2022-08-30 Cilag Gmbh International Mechanisms for proper anvil attachment surgical stapling head assembly
US11627959B2 (en) 2019-06-28 2023-04-18 Cilag Gmbh International Surgical instruments including manual and powered system lockouts
US11298132B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Inlernational Staple cartridge including a honeycomb extension
US11291451B2 (en) 2019-06-28 2022-04-05 Cilag Gmbh International Surgical instrument with battery compatibility verification functionality
US11259803B2 (en) 2019-06-28 2022-03-01 Cilag Gmbh International Surgical stapling system having an information encryption protocol
US11298127B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Interational Surgical stapling system having a lockout mechanism for an incompatible cartridge
US11684434B2 (en) 2019-06-28 2023-06-27 Cilag Gmbh International Surgical RFID assemblies for instrument operational setting control
US11660163B2 (en) 2019-06-28 2023-05-30 Cilag Gmbh International Surgical system with RFID tags for updating motor assembly parameters
US11219455B2 (en) 2019-06-28 2022-01-11 Cilag Gmbh International Surgical instrument including a lockout key
US11497492B2 (en) 2019-06-28 2022-11-15 Cilag Gmbh International Surgical instrument including an articulation lock
US11051807B2 (en) 2019-06-28 2021-07-06 Cilag Gmbh International Packaging assembly including a particulate trap
US11241235B2 (en) 2019-06-28 2022-02-08 Cilag Gmbh International Method of using multiple RFID chips with a surgical assembly
US11553971B2 (en) 2019-06-28 2023-01-17 Cilag Gmbh International Surgical RFID assemblies for display and communication
US11478241B2 (en) 2019-06-28 2022-10-25 Cilag Gmbh International Staple cartridge including projections
US11376098B2 (en) 2019-06-28 2022-07-05 Cilag Gmbh International Surgical instrument system comprising an RFID system
US11224497B2 (en) 2019-06-28 2022-01-18 Cilag Gmbh International Surgical systems with multiple RFID tags
US11638587B2 (en) 2019-06-28 2023-05-02 Cilag Gmbh International RFID identification systems for surgical instruments
US11399837B2 (en) 2019-06-28 2022-08-02 Cilag Gmbh International Mechanisms for motor control adjustments of a motorized surgical instrument
US11246678B2 (en) 2019-06-28 2022-02-15 Cilag Gmbh International Surgical stapling system having a frangible RFID tag
US11344309B2 (en) 2019-07-05 2022-05-31 Covidien Lp Circular stapling instruments
US11844520B2 (en) 2019-12-19 2023-12-19 Cilag Gmbh International Staple cartridge comprising driver retention members
US11559304B2 (en) 2019-12-19 2023-01-24 Cilag Gmbh International Surgical instrument comprising a rapid closure mechanism
US11529137B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Staple cartridge comprising driver retention members
US11234698B2 (en) 2019-12-19 2022-02-01 Cilag Gmbh International Stapling system comprising a clamp lockout and a firing lockout
US11607219B2 (en) 2019-12-19 2023-03-21 Cilag Gmbh International Staple cartridge comprising a detachable tissue cutting knife
US11291447B2 (en) 2019-12-19 2022-04-05 Cilag Gmbh International Stapling instrument comprising independent jaw closing and staple firing systems
US11911032B2 (en) 2019-12-19 2024-02-27 Cilag Gmbh International Staple cartridge comprising a seating cam
US11504122B2 (en) 2019-12-19 2022-11-22 Cilag Gmbh International Surgical instrument comprising a nested firing member
US11529139B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Motor driven surgical instrument
US11576672B2 (en) 2019-12-19 2023-02-14 Cilag Gmbh International Surgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw
US11304696B2 (en) 2019-12-19 2022-04-19 Cilag Gmbh International Surgical instrument comprising a powered articulation system
US11446029B2 (en) 2019-12-19 2022-09-20 Cilag Gmbh International Staple cartridge comprising projections extending from a curved deck surface
US11701111B2 (en) 2019-12-19 2023-07-18 Cilag Gmbh International Method for operating a surgical stapling instrument
US11464512B2 (en) 2019-12-19 2022-10-11 Cilag Gmbh International Staple cartridge comprising a curved deck surface
USD975850S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
USD967421S1 (en) 2020-06-02 2022-10-18 Cilag Gmbh International Staple cartridge
USD975851S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
USD974560S1 (en) 2020-06-02 2023-01-03 Cilag Gmbh International Staple cartridge
USD976401S1 (en) 2020-06-02 2023-01-24 Cilag Gmbh International Staple cartridge
USD975278S1 (en) 2020-06-02 2023-01-10 Cilag Gmbh International Staple cartridge
USD966512S1 (en) 2020-06-02 2022-10-11 Cilag Gmbh International Staple cartridge
US11737748B2 (en) 2020-07-28 2023-08-29 Cilag Gmbh International Surgical instruments with double spherical articulation joints with pivotable links
US11517390B2 (en) 2020-10-29 2022-12-06 Cilag Gmbh International Surgical instrument comprising a limited travel switch
US11844518B2 (en) 2020-10-29 2023-12-19 Cilag Gmbh International Method for operating a surgical instrument
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly
US11717289B2 (en) 2020-10-29 2023-08-08 Cilag Gmbh International Surgical instrument comprising an indicator which indicates that an articulation drive is actuatable
US11896217B2 (en) 2020-10-29 2024-02-13 Cilag Gmbh International Surgical instrument comprising an articulation lock
US11452526B2 (en) 2020-10-29 2022-09-27 Cilag Gmbh International Surgical instrument comprising a staged voltage regulation start-up system
US11779330B2 (en) 2020-10-29 2023-10-10 Cilag Gmbh International Surgical instrument comprising a jaw alignment system
US11617577B2 (en) 2020-10-29 2023-04-04 Cilag Gmbh International Surgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable
USD980425S1 (en) 2020-10-29 2023-03-07 Cilag Gmbh International Surgical instrument assembly
US11534259B2 (en) 2020-10-29 2022-12-27 Cilag Gmbh International Surgical instrument comprising an articulation indicator
US11890010B2 (en) 2020-12-02 2024-02-06 Cllag GmbH International Dual-sided reinforced reload for surgical instruments
US11678882B2 (en) 2020-12-02 2023-06-20 Cilag Gmbh International Surgical instruments with interactive features to remedy incidental sled movements
US11737751B2 (en) 2020-12-02 2023-08-29 Cilag Gmbh International Devices and methods of managing energy dissipated within sterile barriers of surgical instrument housings
US11744581B2 (en) 2020-12-02 2023-09-05 Cilag Gmbh International Powered surgical instruments with multi-phase tissue treatment
US11653915B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Surgical instruments with sled location detection and adjustment features
US11627960B2 (en) 2020-12-02 2023-04-18 Cilag Gmbh International Powered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections
US11653920B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Powered surgical instruments with communication interfaces through sterile barrier
US11849943B2 (en) 2020-12-02 2023-12-26 Cilag Gmbh International Surgical instrument with cartridge release mechanisms
US11730473B2 (en) 2021-02-26 2023-08-22 Cilag Gmbh International Monitoring of manufacturing life-cycle
US11793514B2 (en) 2021-02-26 2023-10-24 Cilag Gmbh International Staple cartridge comprising sensor array which may be embedded in cartridge body
US11812964B2 (en) 2021-02-26 2023-11-14 Cilag Gmbh International Staple cartridge comprising a power management circuit
US11723657B2 (en) 2021-02-26 2023-08-15 Cilag Gmbh International Adjustable communication based on available bandwidth and power capacity
US11744583B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Distal communication array to tune frequency of RF systems
US11696757B2 (en) 2021-02-26 2023-07-11 Cilag Gmbh International Monitoring of internal systems to detect and track cartridge motion status
US11751869B2 (en) 2021-02-26 2023-09-12 Cilag Gmbh International Monitoring of multiple sensors over time to detect moving characteristics of tissue
US11701113B2 (en) 2021-02-26 2023-07-18 Cilag Gmbh International Stapling instrument comprising a separate power antenna and a data transfer antenna
US11749877B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Stapling instrument comprising a signal antenna
US11826042B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Surgical instrument comprising a firing drive including a selectable leverage mechanism
US11717291B2 (en) 2021-03-22 2023-08-08 Cilag Gmbh International Staple cartridge comprising staples configured to apply different tissue compression
US11806011B2 (en) 2021-03-22 2023-11-07 Cilag Gmbh International Stapling instrument comprising tissue compression systems
US11759202B2 (en) 2021-03-22 2023-09-19 Cilag Gmbh International Staple cartridge comprising an implantable layer
US11723658B2 (en) 2021-03-22 2023-08-15 Cilag Gmbh International Staple cartridge comprising a firing lockout
US11826012B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Stapling instrument comprising a pulsed motor-driven firing rack
US11737749B2 (en) 2021-03-22 2023-08-29 Cilag Gmbh International Surgical stapling instrument comprising a retraction system
US11832816B2 (en) 2021-03-24 2023-12-05 Cilag Gmbh International Surgical stapling assembly comprising nonplanar staples and planar staples
US11896218B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Method of using a powered stapling device
US11849945B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Rotary-driven surgical stapling assembly comprising eccentrically driven firing member
US11849944B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Drivers for fastener cartridge assemblies having rotary drive screws
US11786239B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Surgical instrument articulation joint arrangements comprising multiple moving linkage features
US11903582B2 (en) 2021-03-24 2024-02-20 Cilag Gmbh International Leveraging surfaces for cartridge installation
US11857183B2 (en) 2021-03-24 2024-01-02 Cilag Gmbh International Stapling assembly components having metal substrates and plastic bodies
US11786243B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Firing members having flexible portions for adapting to a load during a surgical firing stroke
US11793516B2 (en) 2021-03-24 2023-10-24 Cilag Gmbh International Surgical staple cartridge comprising longitudinal support beam
US11896219B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Mating features between drivers and underside of a cartridge deck
US11744603B2 (en) 2021-03-24 2023-09-05 Cilag Gmbh International Multi-axis pivot joints for surgical instruments and methods for manufacturing same
US11826047B2 (en) 2021-05-28 2023-11-28 Cilag Gmbh International Stapling instrument comprising jaw mounts
US11877745B2 (en) 2021-10-18 2024-01-23 Cilag Gmbh International Surgical stapling assembly having longitudinally-repeating staple leg clusters

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3490675A (en) 1966-10-10 1970-01-20 United States Surgical Corp Instrument for placing lateral gastrointestinal anastomoses
US4300565A (en) 1977-05-23 1981-11-17 American Cyanamid Company Synthetic polyester surgical articles
US5040715A (en) 1989-05-26 1991-08-20 United States Surgical Corporation Apparatus and method for placing staples in laparoscopic or endoscopic procedures
US5307976A (en) 1991-10-18 1994-05-03 Ethicon, Inc. Linear stapling mechanism with cutting means
US5312023A (en) 1991-10-18 1994-05-17 United States Surgical Corporation Self contained gas powered surgical apparatus
US5318221A (en) 1989-05-26 1994-06-07 United States Surgical Corporation Apparatus and method for placing staples in laparoscopic or endoscopic procedures
US5326013A (en) 1991-10-18 1994-07-05 United States Surgical Corporation Self contained gas powered surgical apparatus
US5332142A (en) 1991-10-18 1994-07-26 Ethicon, Inc. Linear stapling mechanism with cutting means
US5915616A (en) 1991-10-18 1999-06-29 United States Surgical Corporation Surgical fastener applying apparatus
US5964394A (en) 1996-03-15 1999-10-12 United States Surgical Corporation Surgical fastener applying device
US6241139B1 (en) 1997-09-23 2001-06-05 Keith L. Milliman Surgical stapling apparatus
US20050245965A1 (en) 2002-06-17 2005-11-03 Orban Iii Joseph P Annular support structures
US20060085034A1 (en) 2004-10-18 2006-04-20 Bettuchi Michael J Support structures and methods of using the same
US20060135992A1 (en) 2004-10-18 2006-06-22 Bettuchi Michael J Annular adhesive structure

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110852A (en) * 1982-07-16 1992-05-05 Rijksuniversiteit Te Groningen Filament material polylactide mixtures
WO1985001651A1 (en) * 1983-10-20 1985-04-25 Vettivetpillai Ketharanathan Biomaterial
US4781183A (en) * 1986-08-27 1988-11-01 American Cyanamid Company Surgical prosthesis
JPH01223969A (en) * 1988-03-04 1989-09-07 Nippon Medical Supply Corp Coated suture
US5468253A (en) * 1993-01-21 1995-11-21 Ethicon, Inc. Elastomeric medical device
AU693797B2 (en) * 1993-07-19 1998-07-09 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5947893A (en) * 1994-04-27 1999-09-07 Board Of Regents, The University Of Texas System Method of making a porous prothesis with biodegradable coatings
US5455110A (en) * 1994-06-29 1995-10-03 Kimberly-Clark Corporation Nonwoven laminated fabrics
US5759569A (en) * 1995-01-10 1998-06-02 The Procter & Gamble Company Biodegradable articles made from certain trans-polymers and blends thereof with other biodegradable components
US5810855A (en) * 1995-07-21 1998-09-22 Gore Enterprise Holdings, Inc. Endoscopic device and method for reinforcing surgical staples
CN1172037C (en) * 1997-05-02 2004-10-20 卡吉尔公司 Degradable polymer fibers, preparation, product, and methods of use
US6355699B1 (en) * 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US6273897B1 (en) * 2000-02-29 2001-08-14 Ethicon, Inc. Surgical bettress and surgical stapling apparatus
US6939358B2 (en) * 2001-12-20 2005-09-06 Gore Enterprise Holdings, Inc. Apparatus and method for applying reinforcement material to a surgical stapler
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
WO2007089878A2 (en) * 2006-01-31 2007-08-09 Angiotech Pharmaceuticals, Inc. Sutures and anti-scarring agents
AU2008223387B2 (en) * 2007-03-06 2014-03-06 Covidien Lp Wound closure material
US8038045B2 (en) * 2007-05-25 2011-10-18 Tyco Healthcare Group Lp Staple buttress retention system
US8062330B2 (en) * 2007-06-27 2011-11-22 Tyco Healthcare Group Lp Buttress and surgical stapling apparatus
US20090048423A1 (en) * 2007-08-15 2009-02-19 Tyco Healthcare Group Lp Phospholipid Copolymers

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3490675A (en) 1966-10-10 1970-01-20 United States Surgical Corp Instrument for placing lateral gastrointestinal anastomoses
US4300565A (en) 1977-05-23 1981-11-17 American Cyanamid Company Synthetic polyester surgical articles
US5318221A (en) 1989-05-26 1994-06-07 United States Surgical Corporation Apparatus and method for placing staples in laparoscopic or endoscopic procedures
US5040715A (en) 1989-05-26 1991-08-20 United States Surgical Corporation Apparatus and method for placing staples in laparoscopic or endoscopic procedures
US5040715B1 (en) 1989-05-26 1994-04-05 United States Surgical Corp Apparatus and method for placing staples in laparoscopic or endoscopic procedures
US5332142A (en) 1991-10-18 1994-07-26 Ethicon, Inc. Linear stapling mechanism with cutting means
US5312023A (en) 1991-10-18 1994-05-17 United States Surgical Corporation Self contained gas powered surgical apparatus
US5326013A (en) 1991-10-18 1994-07-05 United States Surgical Corporation Self contained gas powered surgical apparatus
US5307976A (en) 1991-10-18 1994-05-03 Ethicon, Inc. Linear stapling mechanism with cutting means
US5915616A (en) 1991-10-18 1999-06-29 United States Surgical Corporation Surgical fastener applying apparatus
US5964394A (en) 1996-03-15 1999-10-12 United States Surgical Corporation Surgical fastener applying device
US6241139B1 (en) 1997-09-23 2001-06-05 Keith L. Milliman Surgical stapling apparatus
US6330965B1 (en) 1997-09-23 2001-12-18 United States Surgical Corporation Surgical stapling apparatus
US20050245965A1 (en) 2002-06-17 2005-11-03 Orban Iii Joseph P Annular support structures
US20060085034A1 (en) 2004-10-18 2006-04-20 Bettuchi Michael J Support structures and methods of using the same
US20060135992A1 (en) 2004-10-18 2006-06-22 Bettuchi Michael J Annular adhesive structure

Also Published As

Publication number Publication date
CN101934098A (en) 2011-01-05
AU2010201145A1 (en) 2010-10-21
JP2010240411A (en) 2010-10-28
US20100076489A1 (en) 2010-03-25
EP2243499A3 (en) 2012-11-14
CA2698161A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
EP2243499A2 (en) Wound closure material
US20180125490A1 (en) Wound closure material
US8529819B2 (en) Wound closure material
EP1669093B1 (en) Polyoxyalkylene copolymer blends as biomaterial for drug delivery and surface modification
US9421296B2 (en) Crosslinked fibers and method of making same by extrusion
AU2010215203B2 (en) Medical devices with an activated coating
EP2398511B1 (en) Medical device and method for making the same
US8263105B2 (en) Biomaterial drug delivery and surface modification compositions
JP2020182850A (en) Surgical stapling device
EP3735910A1 (en) Surgical stapling device
CA2740386A1 (en) Process of making bioabsorbable filaments
JP2020182851A (en) Surgical stapling device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 17/12 20060101AFI20121005BHEP

Ipc: A61L 27/54 20060101ALI20121005BHEP

Ipc: A61L 27/20 20060101ALI20121005BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COVIDIEN LP

17P Request for examination filed

Effective date: 20130107

17Q First examination report despatched

Effective date: 20130717

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151001